ERLEC1

UniProt ID: Q96DZ1
Organism: Homo sapiens
Review Status: IN PROGRESS
πŸ“ Provide Detailed Feedback

Gene Description

ERLEC1 (also known as XTP3-B or Erlectin) is an ER-resident lectin containing two mannose 6-phosphate receptor homology (MRH) domains. It functions as a context-dependent triage factor in the endoplasmic reticulum-associated degradation (ERAD) pathway, recognizing misfolded glycoproteins via their trimmed N-glycan sugar moieties and delivering them to the HRD1-SEL1L ubiquitin ligase complex for retrotranslocation and proteasomal degradation. The C-terminal MRH domain (MRH2) mediates glycan binding with specificity for Man9GlcNAc2 (M9) and Man5-type high-mannose N-glycans exposing a terminal alpha-1,6-linked mannose motif (DOI:10.1093/glycob/cwp182, DOI:10.1111/febs.12157). ERLEC1 forms a large ER quality control scaffold complex together with OS-9, BiP (HSPA5), and the HRD1-SEL1L ubiquitin ligase. The long isoform (hXTP3-B-long) associates with this scaffold and can retard ERAD of both glycosylated and non-glycosylated substrates, while the short isoform is excluded from scaffold formation. SEL1L stabilizes ERLEC1 protein; SEL1L depletion causes accelerated ERLEC1 degradation (~40% loss over 10 hours in cycloheximide chase) without change in mRNA levels (DOI:10.1111/febs.12157). Genetic studies reveal that ERLEC1 and OS9 play redundant and antagonistic roles in ERAD: both redundantly promote glycoprotein degradation and stabilize SEL1L-HRD1, but ERLEC1 strongly inhibits degradation of non-glycosylated substrates, with OS9 antagonizing this inhibition, thereby tuning ERAD substrate selectivity (DOI:10.1016/j.molcel.2018.03.026). Mannose trimming by ER mannosidase I is required for substrate delivery from EDEM1 to XTP3-B, consistent with its role as a lectin-based ERAD cargo receptor rather than a chaperone.

Existing Annotations Review

GO Term Evidence Action Reason
GO:0005788 endoplasmic reticulum lumen
IBA
GO_REF:0000033
ACCEPT
Summary: IBA annotation placing ERLEC1 in the ER lumen, inferred from phylogenetic analysis. This is strongly supported by multiple independent experimental studies. Cruciat et al. (PMID:16531414) showed that Erlectin is a luminal resident protein of the endoplasmic reticulum. Hosokawa et al. (PMID:18502753) confirmed ER lumen localization. Christianson et al. (PMID:18264092) also demonstrated ER lumen localization. UniProt annotates subcellular location as ER lumen with experimental evidence. ERLEC1 has a signal peptide (aa 1-33) and lacks a transmembrane domain, consistent with a soluble ER lumen protein retained by the quality control machinery.
Reason: ER lumen localization is a core feature of ERLEC1 function as an ERAD cargo receptor. The IBA annotation is fully consistent with multiple experimental (IDA) demonstrations of ER lumen localization.
Supporting Evidence:
PMID:16531414
Like other members of the MRH family, Erlectin is a luminal resident protein of the endoplasmic reticulum
PMID:18502753
hXTP3-B long isoform associates with the HRD1-SEL1L membrane-anchored ubiquitin ligase complex and BiP, forming a 27 S ER quality control scaffold complex
GO:0030970 retrograde protein transport, ER to cytosol
IBA
GO_REF:0000033
ACCEPT
Summary: IBA annotation for involvement in retrograde protein transport, ER to cytosol, inferred from phylogenetic analysis including yeast Yos9p. ERLEC1/XTP3-B is a key component of the ERAD pathway that delivers misfolded glycoproteins to the HRD1-SEL1L ubiquitin ligase complex for retrotranslocation and proteasomal degradation (PMID:18264092, PMID:18502753). Hosokawa et al. (PMID:18502753) showed that ERLEC1 forms a scaffold complex that provides a platform for recognition and sorting of misfolded proteins prior to retrotranslocation into the cytoplasm. Groisman et al. (PMID:21062743) demonstrated that mannose trimming is required for substrate delivery from EDEM1 to XTP3-B and to late ERAD steps. This term is appropriate as ERLEC1 participates in the process that moves ER proteins to the cytosol for degradation.
Reason: Retrograde protein transport ER to cytosol is a core process that ERLEC1 participates in as an ERAD cargo receptor. The IBA annotation is well supported by experimental evidence from multiple groups showing ERLEC1 functions in delivering misfolded substrates to the retrotranslocation machinery.
Supporting Evidence:
PMID:18502753
this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
PMID:21062743
Our results suggest that mannose trimming enables delivery of a substrate glycoprotein from EDEM1 to late ERAD steps through association with XTP3-B
GO:0005783 endoplasmic reticulum
IEA
GO_REF:0000117
ACCEPT
Summary: IEA annotation from ARBA machine learning placing ERLEC1 in the endoplasmic reticulum. This is correct but less specific than GO:0005788 (endoplasmic reticulum lumen), which is supported by IDA evidence from multiple publications (PMID:16531414, PMID:18264092) and IBA evidence. ERLEC1 is a soluble ER lumen protein, not a membrane-associated protein, so the more specific ER lumen term is more appropriate. However, as an IEA annotation, it is acceptable to retain a broader term that is not incorrect.
Reason: While GO:0005783 (endoplasmic reticulum) is less specific than the experimentally supported GO:0005788 (ER lumen), it is not incorrect. The IEA annotation is a broader but valid computational inference. The more specific ER lumen localization is already captured by separate IDA and IBA annotations.
GO:0005788 endoplasmic reticulum lumen
IEA
GO_REF:0000044
ACCEPT
Summary: IEA annotation mapping ERLEC1 to the ER lumen based on UniProtKB/Swiss-Prot subcellular location vocabulary. UniProt annotates ERLEC1 subcellular location as "Endoplasmic reticulum lumen" with experimental evidence from PMID:16531414 and PMID:18502753. This computational mapping is fully consistent with the experimental data.
Reason: The IEA mapping from UniProt subcellular location to GO:0005788 is correct and consistent with experimental evidence. ERLEC1 ER lumen localization is well established.
GO:0030968 endoplasmic reticulum unfolded protein response
IEA
GO_REF:0000002
MODIFY
Summary: IEA annotation from InterPro (IPR045149, OS-9-like domain) mapping to the ER unfolded protein response. ERLEC1 is part of the ER quality control machinery but its primary role is in ERAD, not the canonical unfolded protein response (UPR) signaling pathway. The UPR is a transcriptional signaling response involving IRE1, PERK, and ATF6 pathways that activates gene expression to cope with ER stress. ERLEC1 does not participate in UPR signaling; rather, it functions downstream as a cargo receptor in ERAD, recognizing misfolded glycoproteins and delivering them to the HRD1-SEL1L complex for retrotranslocation (PMID:18264092, PMID:18502753). The ERAD pathway annotation (GO:0036503) is the more precise term.
Reason: GO:0030968 (ER unfolded protein response) refers to the UPR signaling cascade, not to ERAD per se. ERLEC1 is not a UPR signaling component but rather an ERAD cargo receptor. The correct biological process term is GO:0036503 (ERAD pathway), which is already annotated separately. This IEA annotation likely arises from an overly broad InterPro-to-GO mapping for the OS-9-like domain family.
Proposed replacements: ERAD pathway
GO:0036503 ERAD pathway
IEA
GO_REF:0000002
ACCEPT
Summary: IEA annotation from InterPro (IPR045149, OS-9-like) mapping to the ERAD pathway. This is fully supported by extensive experimental evidence. ERLEC1/XTP3-B is a central component of the ERAD pathway, functioning as a lectin-based cargo receptor that recognizes misfolded glycoproteins and delivers them to the HRD1-SEL1L ubiquitin ligase complex (PMID:18264092, PMID:18502753, PMID:21062743). Groisman et al. (PMID:21062743) specifically demonstrated that mannose trimming is required for substrate delivery from EDEM1 to XTP3-B and to late ERAD steps. Christianson et al. (PMID:18264092) showed that XTP3-B binds to ERAD substrates and through SEL1L to HRD1, and is required for degradation of mutant alpha1-antitrypsin.
Reason: The ERAD pathway is the core biological process in which ERLEC1 participates. The IEA annotation is correct and well supported by experimental evidence from multiple independent studies.
GO:0036503 ERAD pathway
TAS
PMID:21062743
Mannose trimming is required for delivery of a glycoprotein ...
ACCEPT
Summary: TAS annotation for ERAD pathway involvement based on Groisman et al. (PMID:21062743). This paper directly demonstrates that XTP3-B functions in the ERAD pathway by showing that mannose trimming by ER mannosidase I is required for substrate delivery from EDEM1 to XTP3-B, and that inhibition of mannose trimming blocks substrate association with XTP3-B and with E3 ubiquitin ligases HRD1 and SCF(Fbs2). This establishes ERLEC1 as a lectin acting at a late step in the ERAD pathway, after mannose trimming and before ubiquitination and retrotranslocation.
Reason: ERAD pathway involvement is the core function of ERLEC1. The TAS annotation is well supported by the cited reference, which directly demonstrates ERLEC1 function in delivering substrates to late ERAD steps in a mannose-trimming-dependent manner.
Supporting Evidence:
PMID:21062743
Our results suggest that mannose trimming enables delivery of a substrate glycoprotein from EDEM1 to late ERAD steps through association with XTP3-B
PMID:21062743
substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
GO:0051082 unfolded protein binding
IDA
PMID:21062743
Mannose trimming is required for delivery of a glycoprotein ...
REMOVE
Summary: GO:0051082 (unfolded protein binding) is being obsoleted (go-ontology#30962). The suggested replacements are holdase chaperone activity or protein folding chaperone (GO:0044183), neither of which applies to ERLEC1. ERLEC1/XTP3-B is an ER lectin that recognizes misfolded glycoproteins via their trimmed N-glycan moieties as part of the ERAD pathway (PMID:21062743, PMID:18502753). It is not a chaperone. Groisman et al. (PMID:21062743) showed that mannose trimming by ER mannosidase I is required for substrate delivery from EDEM1 to XTP3-B, establishing ERLEC1 as a lectin-based cargo receptor rather than a protein that directly binds unfolded polypeptide chains. Christianson et al. (PMID:18264092) demonstrated that the MRH domains of XTP3-B are required for interaction with SEL1L but not with substrate, and that XTP3-B and OS-9 are components of quality control surveillance pathways that coordinate protein folding with membrane dislocation and ubiquitin conjugation. Hosokawa et al. (PMID:18502753) showed that hXTP3-B forms a scaffold with HRD1-SEL1L and BiP, and that the long isoform retarded ERAD of both glycosylated (NHK) and non-glycosylated (NHK-QQQ) substrates. While ERLEC1 does interact with misfolded proteins, this interaction is in the context of ERAD substrate recognition and delivery to the ubiquitin ligase complex, not chaperone-like unfolded protein binding. The ERAD pathway involvement is already captured by GO:0036503.
Reason: GO:0051082 is being obsoleted. The replacement terms (holdase chaperone, foldase chaperone) do not apply to ERLEC1, which is a lectin-based ERAD cargo receptor, not a chaperone. ERLEC1 recognizes misfolded glycoproteins through their N-glycan sugar moieties (requiring mannose trimming) and delivers them to the HRD1-SEL1L ubiquitin ligase complex for degradation. This is substrate recognition for ERAD targeting, not chaperone-like binding to unfolded polypeptide chains. The relevant biological function is already captured by the ERAD pathway annotation (GO:0036503) and retrograde protein transport annotation (GO:0030970). Similar to SYVN1, ERLEC1 interacts with misfolded proteins as part of the ERAD machinery, which does not constitute unfolded protein binding in the chaperone sense.
Supporting Evidence:
PMID:21062743
Our results suggest that mannose trimming enables delivery of a substrate glycoprotein from EDEM1 to late ERAD steps through association with XTP3-B
PMID:21062743
substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
PMID:18264092
Both proteins contain conserved mannose 6-phosphate receptor homology (MRH) domains, which are required for interaction with SEL1L, but not with substrate
PMID:18264092
XTP3-B and OS-9 are components of distinct, partially redundant, quality control surveillance pathways that coordinate protein folding with membrane dislocation and ubiquitin conjugation in mammalian cells
PMID:18502753
hXTP3-B long isoform associates with the HRD1-SEL1L membrane-anchored ubiquitin ligase complex and BiP, forming a 27 S ER quality control scaffold complex
PMID:18502753
this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation
PMID:16531414
Erlectin functions in N-glycan recognition in the endoplasmic reticulum, suggesting that it may regulate glycoprotein traffic
GO:1904153 negative regulation of retrograde protein transport, ER to cytosol
IMP
PMID:25660456
Identification of ERAD components essential for dislocation ...
KEEP AS NON CORE
Summary: IMP annotation for negative regulation of retrograde protein transport (ER to cytosol) based on Zhong et al. (PMID:25660456). This paper used RNAi knockdown and a dislocation-reconstituted GFP (drGFP) assay to assess the requirement of ERAD components for dislocation of NHK (null Hong Kong variant of alpha1-antitrypsin). The study found that knockdown of 7 of 21 ERAD components enhanced NHK dislocation. If ERLEC1 knockdown enhanced dislocation, this would be consistent with a negative regulatory role. However, this seemingly contradicts the established role of ERLEC1 as a facilitator of ERAD (delivering substrates to the ubiquitin ligase). Hosokawa et al. (PMID:18502753) showed that overexpression of the long isoform of hXTP3-B retarded ERAD of both NHK and NHK-QQQ, which is consistent with a negative regulatory effect when in excess. This paradoxical role may reflect that excess ERLEC1 sequesters substrates or blocks the retrotranslocation channel. The annotation captures the experimental observation but should be interpreted cautiously as possibly reflecting an overexpression/dosage artifact rather than a normal physiological function.
Reason: The annotation captures a real experimental observation (IMP evidence) but the negative regulation of retrotranslocation is likely not the primary physiological role of ERLEC1. Its core function is as a cargo receptor that facilitates ERAD. The negative regulatory effect may reflect dosage-dependent or context-dependent modulation. Hosokawa et al. (PMID:18502753) also observed that hXTP3-B overexpression retards ERAD, consistent with a scaffolding role where excess cargo receptor can sequester substrates away from the retrotranslocation machinery.
Supporting Evidence:
PMID:25660456
knockdown of 7 of the 21 components enhanced NHK dislocation
PMID:18502753
both isoforms retard ERAD of the human alpha(1)-antitrypsin variant null Hong Kong (NHK), a terminally misfolded glycoprotein
PMID:18502753
The hXTP3-B long isoform strongly inhibited ERAD of NHK-QQQ, which lacks all of the N-glycosylation sites of NHK
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-5362412
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-5362412: SYVN1 ubiquitinates Hh C-terminal fragments) placing ERLEC1 in the ER quality control compartment (ERQC). The ERQC is a pericentriolar ER-derived compartment where ERAD machinery concentrates along with misfolded substrates. Groisman et al. (PMID:21062743) showed that XTP3-B associates with ERAD substrates and E3 ligases in a mannose-trimming-dependent manner, consistent with localization to the ERQC. The Reactome entry describes ERLEC1 as a lectin in the ERAD machinery that helps target Hedgehog C-terminal fragments for degradation. This is a reasonable localization annotation for ERLEC1 given its role in ERAD substrate recognition.
Reason: ERQC localization is consistent with ERLEC1 function in ERAD. As a cargo receptor that concentrates with ERAD machinery and substrates, ERLEC1 localizes to this quality control compartment. Multiple Reactome entries reference the same biological role; this is one of many duplicate TAS annotations from different Reactome reactions.
Supporting Evidence:
PMID:21062743
substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-5362437
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-5362437: C-terminal Hh fragments are bound by lectins). This Reactome entry explicitly states that depletion of OS9 and ERLEC1 abrogates degradation of Hh-C fragments, and that they may target Hh-C to the retrotranslocation channel via interaction with SEL1. ERQC localization is appropriate for ERLEC1 given its established role as an ERAD lectin cargo receptor.
Reason: Duplicate ERQC localization annotation from a different Reactome reaction. Same rationale as for R-HSA-5362412: ERLEC1 localizes to the ERQC as part of its ERAD cargo receptor function.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-5362441
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-5362441: C-terminal Hh fragments are recruited to SEL1:SYVN1 at the ER membrane). ERLEC1 participates in recruiting substrates to the SEL1L-SYVN1 complex at the ER membrane, consistent with ERQC localization.
Reason: Duplicate ERQC localization annotation from a different Reactome reaction describing the same ERAD process for Hh fragments.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-5362450
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-5362450: Hh processing variants bind lectins). This entry describes how OS9 and ERLEC1 lectins are required for degradation of Hh processing-defective variants via the ERAD pathway, consistent with ERQC localization.
Reason: Duplicate ERQC localization annotation from a different Reactome reaction describing ERAD of Hedgehog processing variants.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-5362459
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-5362459: VCP-catalyzed ATP hydrolysis promotes the translocation of Hh-C into the cytosol). ERLEC1 is part of the ERAD machinery that operates within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing the VCP-dependent retrotranslocation step for Hh-C fragments in which ERLEC1 participates upstream.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-5387386
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-5387386: Hh processing variants are recruited to SEL1:SYVN at the ER membrane). ERLEC1 participates in recruiting Hh processing variants to the ubiquitin ligase complex.
Reason: Duplicate ERQC localization annotation from a Reactome reaction. Same biological context as other Hh ERAD entries.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-5387389
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-5387389: Hh processing variants are translocated to the cytosol in a VCP-dependent manner). Part of the Hh ERAD pathway in which ERLEC1 acts as cargo receptor.
Reason: Duplicate ERQC localization annotation from a Reactome reaction in the Hh ERAD pathway.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-5483238
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-5483238: Hh processing variants are ubiquitinated). ERLEC1 functions upstream of the ubiquitination step in ERAD, within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing Hh variant ubiquitination in which ERLEC1 participates.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-8866542
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-8866542: VCP-catalyzed ATP hydrolysis promotes the translocation of misfolded CFTR into the cytosol). ERLEC1 is part of the ERAD machinery for misfolded CFTR, consistent with ERQC localization.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CFTR ERAD in which ERLEC1 participates as cargo receptor.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-8866546
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-8866546: RNF5 and RNF185 ubiquitinate misfolded CFTR). ERLEC1 operates within the ERQC as part of the CFTR ERAD pathway.
Reason: Duplicate ERQC localization annotation from a Reactome reaction in the CFTR ERAD pathway.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-8866551
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-8866551: CFTR binds components of the ERAD machinery for ubiquitination and degradation). ERLEC1 is one of the ERAD components that binds misfolded CFTR in the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CFTR binding to ERAD components including ERLEC1.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-8866854
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-8866854: VCP-catalyzed ATP hydrolysis promotes the translocation of CFTR F508del into the cytosol). ERLEC1 participates in ERAD of the common CF-causing CFTR F508del mutation, within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction in the CFTR F508del ERAD pathway.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-8866856
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-8866856: RNF5 and RNF185 ubiquitinate CFTR F508del). ERLEC1 is part of the ERAD machinery for CFTR F508del within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction in the CFTR F508del ERAD pathway.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-8866857
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-8866857: CFTR F508del binds components of the ERAD machinery for ubiquitination and degradation). ERLEC1 is an ERAD component that binds misfolded CFTR F508del.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CFTR F508del ERAD.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-9931264
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-9931264: Active transport of ubiquitinated CD274 from ER to cytosol). ERLEC1 participates in ERAD of CD274 (PD-L1) within the ERQC.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CD274 ERAD.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-9931298
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-9931298: Ubiquitination of CD274 by ERAD complex). ERLEC1 is part of the ERAD complex that ubiquitinates CD274.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CD274 ubiquitination by ERAD.
GO:0044322 endoplasmic reticulum quality control compartment
TAS
Reactome:R-HSA-9931313
ACCEPT
Summary: TAS annotation from Reactome (R-HSA-9931313: p-S195-CD274 binds ERAD complex). ERLEC1 is part of the ERAD complex that binds phosphorylated CD274 for degradation.
Reason: Duplicate ERQC localization annotation from a Reactome reaction describing CD274 ERAD. Last of the 16 duplicate Reactome TAS annotations for ERQC localization, all consistent with ERLEC1 role in ERAD.
GO:0005515 protein binding
IPI
PMID:18502753
Human XTP3-B forms an endoplasmic reticulum quality control ...
MODIFY
Summary: IPI annotation for protein binding based on Hosokawa et al. (PMID:18502753), with UniProtKB:Q13438 (OS-9/OS9) as the interacting partner. This paper showed that hXTP3-B forms an ER quality control scaffold complex with OS-9, HRD1-SEL1L, and BiP. The interaction between ERLEC1 and OS-9 is in the context of the ERAD scaffold complex. While the interaction is real, GO:0005515 (protein binding) is uninformative. A more specific term such as GO:0051787 (misfolded protein binding) would capture the functional context, though the direct interaction with OS-9 is more of a scaffold co-complex interaction. The term could be modified to misfolded protein binding to reflect ERLEC1 function, but since the with/from is OS-9 (a co-complex partner, not a misfolded substrate), the annotation as stated is simply documenting a physical interaction.
Reason: GO:0005515 (protein binding) is uninformative per curation guidelines. ERLEC1 binds misfolded glycoproteins as a cargo receptor. The more informative term is GO:0051787 (misfolded protein binding), which captures ERLEC1 core molecular function of recognizing misfolded glycoprotein substrates for ERAD.
Proposed replacements: misfolded protein binding
Supporting Evidence:
PMID:18502753
this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation
GO:0005515 protein binding
IDA
PMID:16531414
The MRH protein Erlectin is a member of the endoplasmic reti...
MODIFY
Summary: IDA annotation for protein binding based on Cruciat et al. (PMID:16531414). This paper identified Erlectin as a protein that interacts with Kremen2 (KREMEN2), a coreceptor for Dickkopf1 in Wnt signaling. The interaction with Kremen2 is glycosylation-dependent (abolished by Kremen2 deglycosylation) and requires the second MRH domain of Erlectin (G379S mutation abolishes binding). Overexpression of Erlectin inhibited transport of Krm2 to the cell surface. This interaction reflects ERLEC1 lectin activity in glycoprotein quality control. GO:0005515 is uninformative; the functional activity is better captured by misfolded protein binding or N-glycan recognition.
Reason: GO:0005515 (protein binding) is uninformative per curation guidelines. The interaction with Kremen2 via N-glycan recognition represents ERLEC1 lectin function in the ER. The more informative term is GO:0051787 (misfolded protein binding), reflecting ERLEC1 role in recognizing glycoproteins for ER quality control.
Proposed replacements: misfolded protein binding
Supporting Evidence:
PMID:16531414
Erlectin functions in N-glycan recognition in the endoplasmic reticulum, suggesting that it may regulate glycoprotein traffic
PMID:16531414
It contains two MRH domains, of which one is essential for Krm2 binding, and this interaction is abolished by Krm2 deglycosylation
GO:0005515 protein binding
IPI
PMID:18264092
OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1...
MODIFY
Summary: IPI annotation for protein binding based on Christianson et al. (PMID:18264092), with multiple interacting partners (UniProtKB:P11021 HSPA5/BiP, UniProtKB:Q86TM6 SYVN1/HRD1, UniProtKB:Q9UBV2 SEL1L). This paper showed that XTP3-B binds to ERAD substrates and through SEL1L to HRD1. The MRH domains are required for interaction with SEL1L but not with substrate. XTP3-B and OS-9 are components of distinct, partially redundant quality control surveillance pathways. GO:0005515 is uninformative; ERLEC1 interactions with SEL1L and HRD1 reflect its role as a substrate adaptor for the ERAD ubiquitin ligase complex.
Reason: GO:0005515 (protein binding) is uninformative per curation guidelines. The interactions documented here are functionally significant: ERLEC1 binding to SEL1L and HRD1 via its MRH domains reflects its role as a substrate adaptor that bridges misfolded glycoproteins to the E3 ubiquitin ligase complex. The most informative molecular function term would be GO:0051787 (misfolded protein binding), capturing ERLEC1 core activity of recognizing misfolded substrates.
Proposed replacements: misfolded protein binding
Supporting Evidence:
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
PMID:18264092
Both proteins contain conserved mannose 6-phosphate receptor homology (MRH) domains, which are required for interaction with SEL1L, but not with substrate
GO:0005788 endoplasmic reticulum lumen
IDA
PMID:16531414
The MRH protein Erlectin is a member of the endoplasmic reti...
ACCEPT
Summary: IDA annotation for ER lumen localization based on Cruciat et al. (PMID:16531414). This paper demonstrated by immunofluorescence and mass spectrometry that Erlectin is a luminal resident protein of the endoplasmic reticulum. ERLEC1 has a signal peptide (aa 1-33) and lacks a transmembrane domain, consistent with a soluble ER lumen protein.
Reason: ER lumen localization is a well-established core feature of ERLEC1, directly demonstrated by Cruciat et al. The IDA evidence is strong and consistent with the protein sequence (signal peptide, no TM domain) and with other experimental studies.
Supporting Evidence:
PMID:16531414
Like other members of the MRH family, Erlectin is a luminal resident protein of the endoplasmic reticulum
GO:0005788 endoplasmic reticulum lumen
IDA
PMID:18264092
OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1...
ACCEPT
Summary: IDA annotation for ER lumen localization based on Christianson et al. (PMID:18264092). This paper confirmed that XTP3-B/Erlectin is an ER-resident glycoprotein, consistent with ER lumen localization established by Cruciat et al. (PMID:16531414) and Hosokawa et al. (PMID:18502753).
Reason: Independent experimental confirmation of ER lumen localization by a second research group. Consistent with all other evidence.
Supporting Evidence:
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
GO:0005515 protein binding
IPI
PMID:16531414
The MRH protein Erlectin is a member of the endoplasmic reti...
MODIFY
Summary: IPI annotation for protein binding based on Cruciat et al. (PMID:16531414), with UniProtKB:Q8K1S7 (mouse Kremen2) as the interacting partner. This paper identified Erlectin in a proteomic approach as a protein that interacts with Kremen2. The interaction is glycosylation-dependent and requires the MRH domain of Erlectin. GO:0005515 is uninformative; this interaction reflects ERLEC1 lectin activity in N-glycan recognition and glycoprotein quality control.
Reason: GO:0005515 (protein binding) is uninformative per curation guidelines. The interaction with glycosylated Kremen2 via the MRH domain reflects ERLEC1 lectin function. The more informative term is GO:0051787 (misfolded protein binding), as ERLEC1 recognizes glycoproteins in the context of ER quality control.
Proposed replacements: misfolded protein binding
Supporting Evidence:
PMID:16531414
It contains two MRH domains, of which one is essential for Krm2 binding, and this interaction is abolished by Krm2 deglycosylation
PMID:16531414
The overexpression of Erlectin inhibits transport of Krm2 to the cell surface
GO:0051787 misfolded protein binding
IDA
PMID:18264092
OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1...
NEW
Summary: NEW annotation proposed for GO:0051787 (misfolded protein binding). Multiple studies demonstrate that ERLEC1/XTP3-B binds to misfolded glycoproteins in the ER. Christianson et al. (PMID:18264092) showed that XTP3-B binds to ERAD substrates (mutant alpha1-antitrypsin NHK). Hosokawa et al. (PMID:18502753) showed that hXTP3-B forms a scaffold complex for recognition and sorting of misfolded glycoproteins and nonglycosylated proteins. Groisman et al. (PMID:21062743) demonstrated that substrate association with XTP3-B depends on mannose trimming. This term is more informative than the generic GO:0005515 (protein binding) annotations currently present and accurately captures ERLEC1 core molecular function as a lectin that recognizes misfolded glycoprotein substrates for ERAD.
Reason: GO:0051787 (misfolded protein binding) is the most informative molecular function term for ERLEC1. It replaces the uninformative GO:0005515 (protein binding) annotations and provides the correct replacement for the obsolescent GO:0051082 (unfolded protein binding). ERLEC1 specifically binds misfolded glycoproteins (not simply unfolded polypeptides) as a cargo receptor for ERAD.
Supporting Evidence:
PMID:18264092
OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
PMID:18502753
this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation
PMID:21062743
substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
GO:0097466 ubiquitin-dependent glycoprotein ERAD pathway
TAS
PMID:21062743
Mannose trimming is required for delivery of a glycoprotein ...
NEW
Summary: NEW annotation proposed for GO:0097466 (ubiquitin-dependent glycoprotein ERAD pathway). This term is more specific than GO:0036503 (ERAD pathway) and captures the fact that ERLEC1 specifically functions in the glycoprotein-specific branch of ERAD. Groisman et al. (PMID:21062743) showed that mannose trimming of N-glycans is required for substrate delivery from EDEM1 to XTP3-B, establishing ERLEC1 as a lectin that acts specifically in glycoprotein ERAD. The broader GO:0036503 (ERAD pathway) annotation should be retained as well, since Hosokawa et al. (PMID:18502753) showed that the long isoform also affects ERAD of the non-glycosylated NHK-QQQ substrate.
Reason: GO:0097466 is a more specific child term of GO:0036503 that precisely captures ERLEC1 role in the glycoprotein-specific branch of ERAD, where it recognizes trimmed N-glycans on misfolded substrates. This provides higher annotation specificity while the broader ERAD pathway term is retained for the non-glycoprotein ERAD role.
Supporting Evidence:
PMID:21062743
Our results suggest that mannose trimming enables delivery of a substrate glycoprotein from EDEM1 to late ERAD steps through association with XTP3-B
PMID:21062743
the mannosidase inhibitor kifunensine or ERManI knockdown do not affect binding of an ERAD substrate glycoprotein to EDEM1. In contrast, substrate association with XTP3-B and with the E3 ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited

Core Functions

ERLEC1 functions as a lectin-based cargo receptor and context-dependent triage factor in the ERAD pathway. Its C-terminal MRH domain (MRH2) binds Man9GlcNAc2 (M9) and Man5-type high-mannose N-glycans, specifically recognizing a terminal alpha-1,6-linked mannose motif that is exposed during progressive demannosylation of misfolded glycoproteins (DOI:10.1093/glycob/cwp182, DOI:10.1111/febs.12157). ERLEC1 delivers recognized substrates to the HRD1-SEL1L ubiquitin ligase complex for retrotranslocation and proteasomal degradation. Mannose trimming by ER mannosidase I is required for substrate delivery from EDEM1 to ERLEC1. SEL1L stabilizes ERLEC1 protein within the ERAD complex (DOI:10.1111/febs.12157). Genetic studies reveal that ERLEC1 and OS9 have redundant roles in promoting glycoprotein ERAD but antagonistic roles regarding non-glycosylated substrates: ERLEC1 inhibits degradation of non-glycosylated proteins, with OS9 counteracting this inhibition, thereby tuning ERAD substrate selectivity and fidelity (DOI:10.1016/j.molcel.2018.03.026).

Supporting Evidence:
  • PMID:18264092
    OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to ERAD substrates and, through the SEL1L adaptor, to the ER-membrane-embedded ubiquitin ligase Hrd1
  • PMID:21062743
    Our results suggest that mannose trimming enables delivery of a substrate glycoprotein from EDEM1 to late ERAD steps through association with XTP3-B
  • PMID:18502753
    this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation

References

Gene Ontology annotation through association of InterPro records with GO terms
Annotation inferences using phylogenetic trees
Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt
Electronic Gene Ontology annotations created by ARBA machine learning models
The MRH protein Erlectin is a member of the endoplasmic reticulum synexpression group and functions in N-glycan recognition.
OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD.
Human XTP3-B forms an endoplasmic reticulum quality control scaffold with the HRD1-SEL1L ubiquitin ligase complex and BiP.
Mannose trimming is required for delivery of a glycoprotein from EDEM1 to XTP3-B and to late endoplasmic reticulum-associated degradation steps.
Identification of ERAD components essential for dislocation of the null Hong Kong variant of Ξ±-1-antitrypsin (NHK).
DOI:10.1093/glycob/cwp182
Human XTP3-B binds to alpha1-antitrypsin variant nullHong Kong via the C-terminal MRH domain in a glycan-dependent manner.
  • ERLEC1/XTP3-B C-terminal MRH domain mediates binding to Man9GlcNAc2 and Man5-type high-mannose N-glycans with specificity for a terminal ManΞ±1,6Man motif
  • Glycan-dependent binding to misfolded alpha1-antitrypsin NHK was abolished by Endo H treatment (p < 0.001)
DOI:10.1111/febs.12157
Endoplasmic reticulum lectin XTP3-B inhibits endoplasmic reticulum-associated degradation of a misfolded alpha1-antitrypsin variant.
  • ERLEC1/XTP3-B inhibits ERAD of misfolded alpha1-antitrypsin NHK carrying M9 glycans, acting as a negative regulator that may protect newly synthesized glycoproteins from premature degradation
  • Lectin activity is required for substrate engagement but not for SEL1L association
  • SEL1L depletion causes accelerated ERLEC1 degradation (~40% protein loss over 10 hours in cycloheximide chase, mRNA unchanged), indicating SEL1L stabilizes ERLEC1 protein
DOI:10.1016/j.molcel.2018.03.026
Redundant and antagonistic roles of XTP3B and OS9 in decoding glycan and non-glycan degrons in ER-associated degradation.
  • OS9 and XTP3B redundantly promote glycoprotein ERAD and stabilize the SEL1L-HRD1 complex
  • XTP3B strongly inhibits degradation of non-glycosylated substrates, with OS9 antagonizing this inhibition
  • Relative abundance of OS9 vs XTP3B and distribution of glycan vs non-glycan degrons within substrates shapes ERAD fidelity and processivity
DOI:10.1093/glycob/cwq013
The role of MRH domain-containing lectins in ERAD.
  • Review placing ERLEC1/XTP3-B and OS-9 as MRH-domain lectins that decode glycan-based degradation signals and associate with the SEL1L-HRD1 ERAD complex
DOI:10.1038/s41467-024-45633-0
SEL1L-HRD1 interaction is required to form a functional HRD1 ERAD complex.
  • SEL1L hypomorphic variant SEL1L-S658P attenuates SEL1L-HRD1 interaction (~5-fold reduction) while preserving SEL1L-lectin interactions with OS9/ERLEC1
  • ERLEC1 interaction with SEL1L is maintained even when the overall ERAD complex is compromised
Reactome:R-HSA-5362412
SYVN1 ubiquitinates Hh C-terminal fragments
Reactome:R-HSA-5362437
C-terminal Hh fragments are bound by lectins
Reactome:R-HSA-5362441
C-terminal Hh fragments are recruited to SEL1:SYVN1 at the ER membrane
Reactome:R-HSA-5362450
Hh processing variants bind lectins
Reactome:R-HSA-5362459
VCP-catalyzed ATP hydrolysis promotes the translocation of Hh-C into the cytosol
Reactome:R-HSA-5387386
Hh processing variants are recruited to SEL1:SYVN at the ER membrane
Reactome:R-HSA-5387389
Hh processing variants are translocated to the cytosol in a VCP-dependent manner
Reactome:R-HSA-5483238
Hh processing variants are ubiquitinated
Reactome:R-HSA-8866542
VCP-catalyzed ATP hydrolysis promotes the translocation of misfolded CFTR into the cytosol
Reactome:R-HSA-8866546
RNF5 and RNF185 ubiquitinate misfolded CFTR
Reactome:R-HSA-8866551
CFTR binds components of the ERAD machinery for ubiquitination and degradation
Reactome:R-HSA-8866854
VCP-catalyzed ATP hydrolysis promotes the translocation of CFTR F508del into the cytosol
Reactome:R-HSA-8866856
RNF5 and RNF185 ubiquitinate CFTR F508del
Reactome:R-HSA-8866857
CFTR F508del binds components of the ERAD machinery for ubiquitination and degradation
Reactome:R-HSA-9931264
Active transport of ubiquitinated CD274 from ER to cytosol
Reactome:R-HSA-9931298
Ubiquitination of CD274 by ERAD complex
Reactome:R-HSA-9931313
p-S195-CD274 binds ERAD complex

πŸ“š Additional Documentation

Deep Research Falcon

(ERLEC1-deep-research-falcon.md)

provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-20T14:57:14.507946'
end_time: '2026-02-20T15:09:19.495095'
duration_seconds: 724.99
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: ERLEC1
gene_symbol: ERLEC1
uniprot_accession: Q96DZ1
protein_description: 'RecName: Full=Endoplasmic reticulum lectin 1; AltName: Full=ER
lectin; Short=Erlectin; AltName: Full=XTP3-transactivated gene B protein; Flags:
Precursor;'
gene_info: Name=ERLEC1; Synonyms=C2orf30, XTP3TPB; ORFNames=UNQ1878/PRO4321;
organism_full: Homo sapiens (Human).
protein_family: Not specified in UniProt
protein_domains: Man6P_isomerase_rcpt-bd_dom_sf. (IPR009011); MRH_dom. (IPR044865);
OS-9-like. (IPR045149); OS9-like_dom. (IPR012913); PRKCSH (PF07915)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 29


Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

  • UniProt Accession: Q96DZ1
  • Protein Description: RecName: Full=Endoplasmic reticulum lectin 1; AltName: Full=ER lectin; Short=Erlectin; AltName: Full=XTP3-transactivated gene B protein; Flags: Precursor;
  • Gene Information: Name=ERLEC1; Synonyms=C2orf30, XTP3TPB; ORFNames=UNQ1878/PRO4321;
  • Organism (full): Homo sapiens (Human).
  • Protein Family: Not specified in UniProt
  • Key Domains: Man6P_isomerase_rcpt-bd_dom_sf. (IPR009011); MRH_dom. (IPR044865); OS-9-like. (IPR045149); OS9-like_dom. (IPR012913); PRKCSH (PF07915)

MANDATORY VERIFICATION STEPS:

  1. Check if the gene symbol "ERLEC1" matches the protein description above
  2. Verify the organism is correct: Homo sapiens (Human).
  3. Check if protein family/domains align with what you find in literature
  4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'ERLEC1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene ERLEC1 (gene ID: ERLEC1, UniProt: Q96DZ1) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

  • UniProt Accession: Q96DZ1
  • Protein Description: RecName: Full=Endoplasmic reticulum lectin 1; AltName: Full=ER lectin; Short=Erlectin; AltName: Full=XTP3-transactivated gene B protein; Flags: Precursor;
  • Gene Information: Name=ERLEC1; Synonyms=C2orf30, XTP3TPB; ORFNames=UNQ1878/PRO4321;
  • Organism (full): Homo sapiens (Human).
  • Protein Family: Not specified in UniProt
  • Key Domains: Man6P_isomerase_rcpt-bd_dom_sf. (IPR009011); MRH_dom. (IPR044865); OS-9-like. (IPR045149); OS9-like_dom. (IPR012913); PRKCSH (PF07915)

MANDATORY VERIFICATION STEPS:

  1. Check if the gene symbol "ERLEC1" matches the protein description above
  2. Verify the organism is correct: Homo sapiens (Human).
  3. Check if protein family/domains align with what you find in literature
  4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'ERLEC1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene ERLEC1 (gene ID: ERLEC1, UniProt: Q96DZ1) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Title: Functional annotation research report β€” Human ERLEC1 (UniProt Q96DZ1; ER lectin 1 / Erlectin / XTP3TPB / XTP3B)

  1. Target verification (gene/protein identity)
    ERLEC1 (UniProt Q96DZ1) corresponds to the ER-resident lectin historically named XTP3-B / erlectin, a ~483 amino acid protein containing two mannose-6-phosphate receptor homology (MRH) domains implicated in N-glycan binding and ER protein quality control. Foundational experimental characterization described erlectin as an ER luminal resident protein that colocalizes with ER markers in mammalian cells and contains two MRH domains (often denoted D1/D2). (cruciat2006themrhprotein; publication date May 2006; URL https://doi.org/10.1074/jbc.m511872200) (cruciat2006themrhprotein pages 2-3)

  2. Key concepts and definitions (current understanding)
    2.1 ER quality control and ER-associated degradation (ERAD)
    ERAD is a proteostasis pathway that recognizes terminally misfolded proteins in the endoplasmic reticulum (ER) lumen or membrane and targets them for retrotranslocation to the cytosol, ubiquitination, and proteasomal degradation. In mammals, a central ERAD branch is organized around the SEL1L–HRD1 (SYVN1) complex (β€œdislocon”), which recruits luminal substrate-recognition factors, including lectins that decode glycan-based degradation signals on N-glycoproteins. (hosokawa2010theroleof; publication date Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof pages 1-2)

2.2 MRH domains and glycan decoding in ERAD
MRH domains are carbohydrate-recognition modules found in several secretory-pathway lectins; in ERAD-related lectins (including OS9 and ERLEC1/XTP3B), MRH-mediated binding can recognize specific high-mannose N-glycan features that emerge during glycan processing/demannosylation of unproductively folding proteins. (hosokawa2010theroleof; publication date Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof pages 1-2)

  1. Molecular function of ERLEC1 (experimentally supported)
    3.1 Subcellular localization and topology
    Experimental cell biology and biochemical fractionation/protease protection assays support ERLEC1/erlectin as a luminal ER-resident protein. In mammalian cells expressing epitope-tagged erlectin, immunofluorescence microscopy demonstrated colocalization with an ER marker, and microsome/protease protection experiments were used to probe ER localization/topology consistent with luminal residency. (cruciat2006themrhprotein; May 2006; URL https://doi.org/10.1074/jbc.m511872200) (cruciat2006themrhprotein pages 2-3)

A commonly cited schematic places signal sequence and MRH domains in the luminal region of XTP3-B (human long vs short isoforms), consistent with an ER luminal lectin role. (hosokawa2010theroleof; Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof media 808f4af7)

3.2 Domain architecture
ERLEC1/XTP3-B contains two MRH domains. Early work annotated and experimentally used this domain structure to analyze glycan-dependent binding to glycoproteins. (cruciat2006themrhprotein; May 2006; URL https://doi.org/10.1074/jbc.m511872200) (cruciat2006themrhprotein pages 2-3)

A review of MRH lectins in ERAD presents a domain schematic for human XTP3-B with signal sequence and two luminal MRH domains (long and short splice variants). (hosokawa2010theroleof; Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof media 808f4af7)

3.3 Lectin activity and N-glycan binding specificity
Multiple primary studies support that the C-terminal MRH domain (MRH2) mediates ERLEC1 glycan binding.

β€’ Man5-type recognition motif and glycan dependence in cell binding: ERLEC1/XTP3-B binding to Lec1 cell glycans depended on the C-terminal MRH domain and was abolished by Endo H treatment, supporting high-mannose N-glycan dependence. The study further implicated a terminal ManΞ±1,6Man motif (within Man5GlcNAc2 context) in recognition and demonstrated statistically significant Endo H effects (reported p < 0.001 in binding assays). (Yamaguchi et al., Glycobiology; publication date Nov 2010; URL https://doi.org/10.1093/glycob/cwp182) (yamaguchi2010humanxtp3bbinds pages 1-2)

β€’ M9 (Man9GlcNAc2) binding in vitro and in vivo: Using frontal affinity chromatography and in vitro binding assays, ERLEC1/XTP3-B’s C-terminal MRH domain showed specific binding to Man9GlcNAc2 (M9), whereas the N-terminal MRH domain did not show binding under the tested conditions. (Fujimori et al., FEBS Journal; publication date Mar 2013; URL https://doi.org/10.1111/febs.12157) (fujimori2013endoplasmicreticulumlectin pages 2-4, fujimori2013endoplasmicreticulumlectin pages 1-2)

β€’ Connection to demannosylation signals recognized by ER lectins: A mechanistic genetic study framed glycoprotein ERAD as depending on lectin decoding of progressively demannosylated high-mannose glycans (Man5–7GlcNAc2) exposing a terminal Ξ±1,6-linked mannose, and positioned XTP3B/ERLEC1 as one of the lectins participating in this decoding. (van der Goot et al., Molecular Cell; publication date May 2018; URL https://doi.org/10.1016/j.molcel.2018.03.026) (goot2018redundantandantagonistic pages 1-3)

These findings indicate ERLEC1 is a lectin rather than an enzyme; its primary biochemical β€œsubstrate specificity” is for defined high-mannose N-glycan features (Man5/Man9 and, in ERAD contexts, demannosylated high-mannose signals). (fujimori2013endoplasmicreticulumlectin pages 2-4, goot2018redundantandantagonistic pages 1-3, yamaguchi2010humanxtp3bbinds pages 1-2)

3.4 Protein–protein interactions and ERAD complex membership
3.4.1 Association with SEL1L–HRD1 ERAD machinery
ERLEC1/XTP3-B associates with the HRD1–SEL1L ubiquitin ligase complex, consistent with being a stable component of a large ERAD complex. Co-fractionation and interaction evidence indicates ERLEC1 connects luminal recognition to the membrane ubiquitination/retrotranslocation machinery. (Fujimori et al., FEBS Journal; Mar 2013; URL https://doi.org/10.1111/febs.12157) (fujimori2013endoplasmicreticulumlectin pages 2-4)

A review schematic of mammalian ERAD explicitly depicts OS-9 and XTP3-B associating with the SEL1L–HRD1 complex in the pathway that routes misfolded glycoproteins toward degradation. (hosokawa2010theroleof; Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof media bdd75ee9)

3.4.2 Stabilization by SEL1L
SEL1L appears to stabilize ERLEC1 protein. In SEL1L depletion experiments, ERLEC1/XTP3-B displayed accelerated degradation in a cycloheximide chase (approximately 40% loss over 10 hours, with unchanged mRNA), consistent with proteasomal turnover when not assembled into the complex. (Fujimori et al., FEBS Journal; Mar 2013; URL https://doi.org/10.1111/febs.12157) (fujimori2013endoplasmicreticulumlectin pages 2-4)

3.4.3 Interactions preserved in SEL1L hypomorphic variant models (2024)
In a Nature Communications 2024 study dissecting SEL1L–HRD1 complex formation, ERLEC1 is listed among SEL1L-interacting components (β€œincluding OS9 and ERLEC1”), and a SEL1L hypomorphic variant (SEL1LS658P) was reported to attenuate SEL1L–HRD1 interaction while having no detectable effect on SEL1L–lectin interactions with OS9/ERLEC1. Quantitatively, the SEL1L–HRD1 interaction was reduced by ~5-fold in knock-in livers; SEL1L and HRD1 levels were reduced by 20% and 60% in KI cerebellum, and by 20% and 30% in KI HEK293T cells (relative to WT), respectively. (Lin et al., Nature Communications; publication date Feb 2024; URL https://doi.org/10.1038/s41467-024-45633-0) (lin2024sel1lhrd1interactionis pages 6-7)

3.4.4 Expert synthesis: ERLEC1 as a luminal β€œbinder/escort” to SEL1L–HRD1
A 2024 JCI expert commentary summarized ERLEC1/XTP3B (along with OS9 and EDEM1) as luminal factors that bind misfolded proteins in the ER lumen and bring them to SEL1L/SEL1L–HRD1 for ubiquitination and degradation, reflecting a consensus pathway model in which lectins act upstream of the dislocon. (Umphred-Wilson & Adoro, J Clin Invest; publication date Jan 2024; URL https://doi.org/10.1172/jci175448) (umphredwilson2024hypomorphichumansel1l pages 1-2)

  1. Functional role in ERAD and proteostasis (including substrate dependence)
    4.1 Substrate-specific inhibitory role (negative regulator) β€” misfolded Ξ±1-antitrypsin NHK
    A primary mechanistic study concluded that ERLEC1/XTP3-B inhibits ER-associated degradation of a misfolded Ξ±1-antitrypsin variant (NHK) carrying M9 glycans, proposing that ERLEC1 can act as a negative regulator that protects newly synthesized/immature glycoproteins from premature degradation. The same study linked lectin activity (glycan binding) to substrate engagement (NHK binding required lectin activity), while ERLEC1’s association with SEL1L did not require lectin activity. (Fujimori et al., FEBS Journal; Mar 2013; URL https://doi.org/10.1111/febs.12157) (fujimori2013endoplasmicreticulumlectin pages 1-2)

Complementary evidence showed ERLEC1 binds an ERAD substrate (Ξ±1-antitrypsin nullHong Kong) via the C-terminal MRH domain in a glycan-dependent manner. (Yamaguchi et al., Glycobiology; Nov 2010; URL https://doi.org/10.1093/glycob/cwp182) (yamaguchi2010humanxtp3bbinds pages 1-1, yamaguchi2010humanxtp3bbinds pages 1-2)

4.2 Redundant and antagonistic roles with OS9 (triage of glycan vs non-glycan degrons)
A genetic deletion study of the two major metazoan Yos9 orthologs (OS9 and XTP3B/ERLEC1) concluded:
β€’ OS9 and XTP3B redundantly promote glycoprotein degradation and stabilize the SEL1L/HRD1 complex.
β€’ XTP3B strongly inhibits degradation of non-glycosylated substrates, and OS9 antagonizes this inhibition.
β€’ The relative abundance of OS9 vs XTP3B and the distribution of glycan and non-glycan degrons within the same substrate influence ERAD β€œfidelity and processivity,” shaping protein fate in the early secretory pathway.
(van der Goot et al., Molecular Cell; May 2018; URL https://doi.org/10.1016/j.molcel.2018.03.026) (goot2018redundantandantagonistic pages 1-3)

These findings reconcile apparently conflicting observations (ERLEC1 inhibiting ERAD for some substrates) by supporting a model in which ERLEC1 can both facilitate glycoprotein ERAD (with OS9) and restrain degradation of certain proteins (especially non-glycosylated substrates and specific glycoprotein contexts), thereby tuning triage rather than acting as a simple β€œon/off” ERAD factor. (goot2018redundantandantagonistic pages 1-3, fujimori2013endoplasmicreticulumlectin pages 1-2)

  1. Pathways and cellular processes involving ERLEC1
    5.1 Core pathway placement: SEL1L–HRD1 ERAD branch
    ERLEC1 is best supported as a luminal substrate-recognition/triage factor positioned upstream of and interacting with the SEL1L–HRD1 ERAD complex. The mammalian pathway model illustrates ERLEC1/XTP3-B and OS9 associating with SEL1L–HRD1 and participating in routing misfolded glycoproteins toward ubiquitination and proteasomal degradation. (hosokawa2010theroleof; Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof media bdd75ee9)

5.2 Crosstalk with ER stress (UPR) as a functional context
Because ERAD is a major ER proteostasis pathway, ERLEC1 function is often discussed in the context of ER stress/unfolded protein response (UPR). In multiple myeloma, experimental disruption of ERAD genes induces BiP (an ER stress marker), illustrating that perturbing ERAD increases ER stress in secretory-lineage cancers (see Section 6.1). (de Matos Simoes et al., Nature Cancer; May 2023; URL https://doi.org/10.1038/s43018-023-00550-x) (simoes2023genomescalefunctionalgenomics pages 9-10)

  1. Recent developments (2023–2024 prioritized)
    6.1 Cancer vulnerabilities: multiple myeloma dependency mapping (Nature Cancer 2023)
    A genome-scale functional genomics study in multiple myeloma (MM) used CRISPR dependency mapping to identify MM-preferentially essential genes. The authors note that several ERAD-related genes, explicitly including ERLEC1, are more essential in MM versus B-cell lymphomas, aligning ERAD/proteostasis as a lineage-specific vulnerability of immunoglobulin-secreting malignancies. (de Matos Simoes et al., Nature Cancer; publication date May 2023; URL https://doi.org/10.1038/s43018-023-00550-x) (simoes2023genomescalefunctionalgenomics pages 7-9)

In the same work, the authors contextualize ERAD as a biological vulnerability in MM due to proteostatic stress from immunoglobulin production and experimentally validate ERAD gene knockouts (e.g., UBE2J1, SYVN1, HERPUD1) as affecting MM viability and ER stress markers. Although ERLEC1 is not individually validated in the excerpted sections, it is grouped within ERAD-related dependencies enriched in MM. (de Matos Simoes et al., Nature Cancer; May 2023; URL https://doi.org/10.1038/s43018-023-00550-x) (simoes2023genomescalefunctionalgenomics pages 9-10)

6.2 ERAD machinery in human disease: SEL1L/HRD1 variants (JCI 2024) and mechanistic definition of ERAD complex assembly (Nat Comms 2024)
Mechanistic work in 2024 emphasized that proper SEL1L–HRD1 interaction is required to form a functional HRD1 ERAD complex and documented that SEL1L–lectin interactions with OS9/ERLEC1 are preserved despite compromised SEL1L–HRD1 binding in a hypomorphic variant model. (Lin et al., Nature Communications; Feb 2024; URL https://doi.org/10.1038/s41467-024-45633-0) (lin2024sel1lhrd1interactionis pages 6-7)

An authoritative 2024 JCI commentary framed ERLEC1/XTP3B as part of the luminal recognition/escort layer (with OS9 and EDEM1) that brings misfolded proteins to SEL1L–HRD1 for degradation, highlighting expert consensus on ERLEC1’s pathway role as ERAD biology becomes clinically relevant through pathogenic SEL1L/HRD1 variants. (Umphred-Wilson & Adoro, J Clin Invest; Jan 2024; URL https://doi.org/10.1172/jci175448) (umphredwilson2024hypomorphichumansel1l pages 1-2)

6.3 Disease-associated transcriptomic signatures featuring ERLEC1
6.3.1 Cancer-therapy–related cognitive impairment model (Brain Sciences 2023)
In a mouse model of cognitive impairment after cancer therapy, combined doxorubicin + hindlimb radiation (DOX-RT) altered brain gene expression and significantly increased Erlec1 expression. Table data reported Erlec1 mean normalized counts: control 497.7 (SEM 14.78), DOX 533.0 (SEM 8.97), RT 498.3 (SEM 8.82), DOX-RT 558.3 (SEM 8.70); overall ANOVA F = 7.634, p = 0.0014; with RT vs DOX-RT Tukey p = 0.0037 (n = 6 mice per group). (Demos-Davies et al., Brain Sciences; publication date Dec 2023; URL https://doi.org/10.3390/brainsci14010022) (demosdavies2023thedistantmolecular pages 8-10)

6.3.2 Interstitial cystitis host gene expression (Frontiers in Immunology 2024)
A study combining Mendelian randomization and bulk RNA-seq in interstitial cystitis reported ERLEC1 among upregulated β€œhub genes” (along with CHAC2, ASB3, STAT5A, STAT3), suggesting ERLEC1 can appear in inflammatory/autoimmune-associated transcriptional programs. (Fu et al., Frontiers in Immunology; publication date Sep 2024; URL https://doi.org/10.3389/fimmu.2024.1395580) (fu2024gutmicrobiotaand pages 9-10)

  1. Current applications and real-world implementations
    7.1 Functional genomics and target discovery in secretory cancers
    ERLEC1’s inclusion among ERAD-related genes more essential in MM vs B-cell lymphomas supports its use as part of an ER proteostasis vulnerability map for secretory-lineage malignancies; such maps inform prioritization of pathway nodes for therapeutic development, especially in combination with proteasome inhibitors that induce ER stress. (de Matos Simoes et al., Nature Cancer; May 2023; URL https://doi.org/10.1038/s43018-023-00550-x) (simoes2023genomescalefunctionalgenomics pages 7-9, simoes2023genomescalefunctionalgenomics pages 9-10)

7.2 Biomarker/omics signatures (expression panels)
ERLEC1 appears in differential-expression panels in diverse contexts (therapy-induced brain expression changes; inflammatory bladder disease hub-gene set), illustrating a real-world use pattern where ERLEC1 is a feature in transcriptomic signatures rather than a stand-alone biomarker with a mature clinical assay. (demosdavies2023thedistantmolecular pages 8-10, fu2024gutmicrobiotaand pages 9-10)

7.3 Mechanistic pathway modeling of ERAD
The ERAD model depicting ERLEC1 (XTP3-B) together with OS-9 interfacing with the SEL1L–HRD1 complex is used as a canonical representation for how N-glycan-binding lectins feed substrates into the ubiquitination/retrotranslocation machinery. (hosokawa2010theroleof; Jun 2010; URL https://doi.org/10.1093/glycob/cwq013) (hosokawa2010theroleof media bdd75ee9)

  1. Expert opinion and analysis (authoritative synthesis)
    Two complementary lines of evidence shape expert interpretation of ERLEC1 function:
    β€’ Biochemical/interaction studies support ERLEC1 as a lectin bound to SEL1L–HRD1 and capable of binding high-mannose glycans (Man5/Man9) via its C-terminal MRH domain. (fujimori2013endoplasmicreticulumlectin pages 2-4, yamaguchi2010humanxtp3bbinds pages 1-2)
    β€’ Genetic dissection of ER lectins supports ERLEC1 as a triage regulator that (i) redundantly promotes glycoprotein ERAD and stabilizes the SEL1L–HRD1 complex, but (ii) inhibits degradation of non-glycosylated proteins and can restrain ERAD in certain substrate contexts, with OS9 acting antagonistically in the non-glycosylated case. (goot2018redundantandantagonistic pages 1-3)

This supports a current model in which ERLEC1 is not merely a β€œdegradation receptor,” but a context-dependent triage factor controlling flux and selectivity in ER protein quality control, potentially balancing retention/refolding opportunities versus commitment to degradation. (goot2018redundantandantagonistic pages 1-3, fujimori2013endoplasmicreticulumlectin pages 1-2)

  1. Key statistics and quantitative data highlights
    β€’ SEL1L stabilizes ERLEC1 protein: ~40% ERLEC1 loss over a 10-hour cycloheximide chase upon SEL1L depletion (protein turnover effect; mRNA unchanged). (Fujimori et al., FEBS J; Mar 2013; URL https://doi.org/10.1111/febs.12157) (fujimori2013endoplasmicreticulumlectin pages 2-4)
    β€’ Glycan-dependence statistical support: Endo H treatment significantly reduced XTP3-B binding in cell-binding assays (reported p < 0.001). (Yamaguchi et al., Glycobiology; Nov 2010; URL https://doi.org/10.1093/glycob/cwp182) (yamaguchi2010humanxtp3bbinds pages 1-2)
    β€’ ERLEC1 differential expression in a cancer-therapy brain model: Erlec1 ANOVA F = 7.634, p = 0.0014; control mean 497.7 vs DOX-RT mean 558.3 normalized counts (n = 6/group), with RT vs DOX-RT Tukey p = 0.0037. (Demos-Davies et al., Brain Sciences; Dec 2023; URL https://doi.org/10.3390/brainsci14010022) (demosdavies2023thedistantmolecular pages 8-10)
    β€’ ERAD complex perturbation with preserved ERLEC1 interaction: SEL1L–HRD1 interaction reduced ~5-fold in knock-in livers; SEL1L and HRD1 levels reduced by 20% and 60% in KI cerebellum (and by 20% and 30% in KI HEK293T cells). (Lin et al., Nat Comms; Feb 2024; URL https://doi.org/10.1038/s41467-024-45633-0) (lin2024sel1lhrd1interactionis pages 6-7)

  2. Limitations and open questions for ERLEC1 functional annotation
    Despite clear evidence for ER residency, MRH-domain–mediated glycan binding, and ERAD pathway involvement, several items remain incompletely resolved in the provided literature subset:
    β€’ High-resolution structural determinants of glycan binding and how ERLEC1’s Man5/Man9 binding relates quantitatively to ERAD β€œmannose-trimmed” signals (e.g., Man5–7 terminal Ξ±1,6 mannose exposure) across diverse substrates.
    β€’ Substrate rules that determine whether ERLEC1 promotes ERAD, inhibits ERAD, or stabilizes the dislocon, especially in relation to OS9 abundance and the presence of non-glycan degrons.
    These questions are directly motivated by the context-dependent behaviors reported across substrate-focused and genetic studies. (goot2018redundantandantagonistic pages 1-3, fujimori2013endoplasmicreticulumlectin pages 1-2)

Selected primary references (publication date; URL)
β€’ Cruciat CM et al. J Biol Chem (May 2006). https://doi.org/10.1074/jbc.m511872200 (cruciat2006themrhprotein pages 2-3)
β€’ Hosokawa N et al. Glycobiology (Jun 2010). https://doi.org/10.1093/glycob/cwq013 (hosokawa2010theroleof pages 1-2)
β€’ Yamaguchi D et al. Glycobiology (Nov 2010). https://doi.org/10.1093/glycob/cwp182 (yamaguchi2010humanxtp3bbinds pages 1-2)
β€’ Fujimori T et al. FEBS J (Mar 2013). https://doi.org/10.1111/febs.12157 (fujimori2013endoplasmicreticulumlectin pages 2-4)
β€’ van der Goot AT et al. Mol Cell (May 2018). https://doi.org/10.1016/j.molcel.2018.03.026 (goot2018redundantandantagonistic pages 1-3)

Selected recent references (2023–2024 prioritized)
β€’ de Matos Simoes R et al. Nature Cancer (May 2023). https://doi.org/10.1038/s43018-023-00550-x (simoes2023genomescalefunctionalgenomics pages 7-9)
β€’ Demos-Davies KM et al. Brain Sciences (Dec 2023). https://doi.org/10.3390/brainsci14010022 (demosdavies2023thedistantmolecular pages 8-10)
β€’ Lin LGL et al. Nature Communications (Feb 2024). https://doi.org/10.1038/s41467-024-45633-0 (lin2024sel1lhrd1interactionis pages 6-7)
β€’ Umphred-Wilson K, Adoro S. J Clin Invest (Jan 2024). https://doi.org/10.1172/jci175448 (umphredwilson2024hypomorphichumansel1l pages 1-2)
β€’ Fu C et al. Frontiers in Immunology (Sep 2024). https://doi.org/10.3389/fimmu.2024.1395580 (fu2024gutmicrobiotaand pages 9-10)

References

  1. (cruciat2006themrhprotein pages 2-3): Cristina-Maria Cruciat, Christine Hassler, and Christof Niehrs. The mrh protein erlectin is a member of the endoplasmic reticulum synexpression group and functions in n-glycan recognition*. Journal of Biological Chemistry, 281:12986-12993, May 2006. URL: https://doi.org/10.1074/jbc.m511872200, doi:10.1074/jbc.m511872200. This article has 47 citations and is from a domain leading peer-reviewed journal.

  2. (hosokawa2010theroleof pages 1-2): N. Hosokawa, Y. Kamiya, and Koichi Kato. The role of mrh domain-containing lectins in erad. Glycobiology, 20 6:651-60, Jun 2010. URL: https://doi.org/10.1093/glycob/cwq013, doi:10.1093/glycob/cwq013. This article has 89 citations and is from a peer-reviewed journal.

  3. (hosokawa2010theroleof media 808f4af7): N. Hosokawa, Y. Kamiya, and Koichi Kato. The role of mrh domain-containing lectins in erad. Glycobiology, 20 6:651-60, Jun 2010. URL: https://doi.org/10.1093/glycob/cwq013, doi:10.1093/glycob/cwq013. This article has 89 citations and is from a peer-reviewed journal.

  4. (yamaguchi2010humanxtp3bbinds pages 1-2): D. Yamaguchi, D. Hu, N. Matsumoto, and K. Yamamoto. Human xtp3-b binds to 1-antitrypsin variant nullhong kong via the c-terminal mrh domain in a glycan-dependent manner. Glycobiology, 20:348-355, Nov 2010. URL: https://doi.org/10.1093/glycob/cwp182, doi:10.1093/glycob/cwp182. This article has 61 citations and is from a peer-reviewed journal.

  5. (fujimori2013endoplasmicreticulumlectin pages 2-4): Tsutomu Fujimori, Yukiko Kamiya, Kazuhiro Nagata, Koichi Kato, and Nobuko Hosokawa. Endoplasmic reticulum lectin xtp3‐b inhibits endoplasmic reticulum‐associated degradation of a misfolded Ξ±1‐antitrypsin variant. The FEBS Journal, 280:1563-1575, Mar 2013. URL: https://doi.org/10.1111/febs.12157, doi:10.1111/febs.12157. This article has 50 citations.

  6. (fujimori2013endoplasmicreticulumlectin pages 1-2): Tsutomu Fujimori, Yukiko Kamiya, Kazuhiro Nagata, Koichi Kato, and Nobuko Hosokawa. Endoplasmic reticulum lectin xtp3‐b inhibits endoplasmic reticulum‐associated degradation of a misfolded Ξ±1‐antitrypsin variant. The FEBS Journal, 280:1563-1575, Mar 2013. URL: https://doi.org/10.1111/febs.12157, doi:10.1111/febs.12157. This article has 50 citations.

  7. (goot2018redundantandantagonistic pages 1-3): Annemieke T. van der Goot, Margaret M.P. Pearce, Dara E. Leto, Thomas A. Shaler, and Ron R. Kopito. Redundant and antagonistic roles of xtp3b and os9 in decoding glycan and non-glycan degrons in er-associated degradation. Molecular cell, 70 3:516-530.e6, May 2018. URL: https://doi.org/10.1016/j.molcel.2018.03.026, doi:10.1016/j.molcel.2018.03.026. This article has 71 citations and is from a highest quality peer-reviewed journal.

  8. (hosokawa2010theroleof media bdd75ee9): N. Hosokawa, Y. Kamiya, and Koichi Kato. The role of mrh domain-containing lectins in erad. Glycobiology, 20 6:651-60, Jun 2010. URL: https://doi.org/10.1093/glycob/cwq013, doi:10.1093/glycob/cwq013. This article has 89 citations and is from a peer-reviewed journal.

  9. (lin2024sel1lhrd1interactionis pages 6-7): Liangguang Leo Lin, Huilun Helen Wang, Brent Pederson, Xiaoqiong Wei, Mauricio Torres, You Lu, Zexin Jason Li, Xiaodan Liu, Hancheng Mao, Hui Wang, Linyao Elina Zhou, Zhen Zhao, Shengyi Sun, and Ling Qi. Sel1l-hrd1 interaction is required to form a functional hrd1 erad complex. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-45633-0, doi:10.1038/s41467-024-45633-0. This article has 36 citations and is from a highest quality peer-reviewed journal.

  10. (umphredwilson2024hypomorphichumansel1l pages 1-2): Katharine Umphred-Wilson and Stanley Adoro. Hypomorphic human sel1l and hrd1 variants uncouple multilayered er-associated degradation machinery. The Journal of Clinical Investigation, Jan 2024. URL: https://doi.org/10.1172/jci175448, doi:10.1172/jci175448. This article has 4 citations.

  11. (yamaguchi2010humanxtp3bbinds pages 1-1): D. Yamaguchi, D. Hu, N. Matsumoto, and K. Yamamoto. Human xtp3-b binds to 1-antitrypsin variant nullhong kong via the c-terminal mrh domain in a glycan-dependent manner. Glycobiology, 20:348-355, Nov 2010. URL: https://doi.org/10.1093/glycob/cwp182, doi:10.1093/glycob/cwp182. This article has 61 citations and is from a peer-reviewed journal.

  12. (simoes2023genomescalefunctionalgenomics pages 9-10): Ricardo de Matos Simoes, Ryosuke Shirasaki, Sondra L. Downey-Kopyscinski, Geoffrey M. Matthews, Benjamin G. Barwick, Vikas A. Gupta, DaphnΓ© DupΓ©rΓ©-Richer, Shizuka Yamano, Yiguo Hu, Michal Sheffer, Eugen Dhimolea, Olga Dashevsky, Sara Gandolfi, Kazuya Ishiguro, Robin M. Meyers, Jordan G. Bryan, Neekesh V. Dharia, Paul J. Hengeveld, Johanna B. BrΓΌggenthies, Huihui Tang, Andrew J. Aguirre, Quinlan L. Sievers, Benjamin L. Ebert, Brian J. Glassner, Christopher J. Ott, James E. Bradner, Nicholas P. Kwiatkowski, Daniel Auclair, Joan Levy, Jonathan J. Keats, Richard W. J. Groen, Nathanael S. Gray, Aedin C. Culhane, James M. McFarland, Joshua M. Dempster, Jonathan D. Licht, Lawrence H. Boise, William C. Hahn, Francisca Vazquez, Aviad Tsherniak, and Constantine S. Mitsiades. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nature Cancer, 4:754-773, May 2023. URL: https://doi.org/10.1038/s43018-023-00550-x, doi:10.1038/s43018-023-00550-x. This article has 38 citations and is from a highest quality peer-reviewed journal.

  13. (simoes2023genomescalefunctionalgenomics pages 7-9): Ricardo de Matos Simoes, Ryosuke Shirasaki, Sondra L. Downey-Kopyscinski, Geoffrey M. Matthews, Benjamin G. Barwick, Vikas A. Gupta, DaphnΓ© DupΓ©rΓ©-Richer, Shizuka Yamano, Yiguo Hu, Michal Sheffer, Eugen Dhimolea, Olga Dashevsky, Sara Gandolfi, Kazuya Ishiguro, Robin M. Meyers, Jordan G. Bryan, Neekesh V. Dharia, Paul J. Hengeveld, Johanna B. BrΓΌggenthies, Huihui Tang, Andrew J. Aguirre, Quinlan L. Sievers, Benjamin L. Ebert, Brian J. Glassner, Christopher J. Ott, James E. Bradner, Nicholas P. Kwiatkowski, Daniel Auclair, Joan Levy, Jonathan J. Keats, Richard W. J. Groen, Nathanael S. Gray, Aedin C. Culhane, James M. McFarland, Joshua M. Dempster, Jonathan D. Licht, Lawrence H. Boise, William C. Hahn, Francisca Vazquez, Aviad Tsherniak, and Constantine S. Mitsiades. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nature Cancer, 4:754-773, May 2023. URL: https://doi.org/10.1038/s43018-023-00550-x, doi:10.1038/s43018-023-00550-x. This article has 38 citations and is from a highest quality peer-reviewed journal.

  14. (demosdavies2023thedistantmolecular pages 8-10): Kimberly M. Demos-Davies, Jessica Lawrence, Clara Ferreira, and Davis Seelig. The distant molecular effects on the brain by cancer treatment. Brain Sciences, 14:22, Dec 2023. URL: https://doi.org/10.3390/brainsci14010022, doi:10.3390/brainsci14010022. This article has 2 citations.

  15. (fu2024gutmicrobiotaand pages 9-10): Chaowei Fu, Yu Zhao, Xiang Zhou, Jing Lv, Shengkai Jin, Yuhua Zhou, Fengping Liu, and Ninghan Feng. Gut microbiota and interstitial cystitis: exploring the gut-bladder axis through mendelian randomization, biological annotation and bulk rna sequencing. Frontiers in Immunology, Sep 2024. URL: https://doi.org/10.3389/fimmu.2024.1395580, doi:10.3389/fimmu.2024.1395580. This article has 9 citations and is from a peer-reviewed journal.

Citations

  1. cruciat2006themrhprotein pages 2-3
  2. hosokawa2010theroleof pages 1-2
  3. goot2018redundantandantagonistic pages 1-3
  4. fujimori2013endoplasmicreticulumlectin pages 2-4
  5. fujimori2013endoplasmicreticulumlectin pages 1-2
  6. simoes2023genomescalefunctionalgenomics pages 9-10
  7. simoes2023genomescalefunctionalgenomics pages 7-9
  8. demosdavies2023thedistantmolecular pages 8-10
  9. fu2024gutmicrobiotaand pages 9-10
  10. https://doi.org/10.1074/jbc.m511872200
  11. https://doi.org/10.1093/glycob/cwq013
  12. https://doi.org/10.1093/glycob/cwp182
  13. https://doi.org/10.1111/febs.12157
  14. https://doi.org/10.1016/j.molcel.2018.03.026
  15. https://doi.org/10.1038/s41467-024-45633-0
  16. https://doi.org/10.1172/jci175448
  17. https://doi.org/10.1038/s43018-023-00550-x
  18. https://doi.org/10.3390/brainsci14010022
  19. https://doi.org/10.3389/fimmu.2024.1395580
  20. https://doi.org/10.1074/jbc.m511872200,
  21. https://doi.org/10.1093/glycob/cwq013,
  22. https://doi.org/10.1093/glycob/cwp182,
  23. https://doi.org/10.1111/febs.12157,
  24. https://doi.org/10.1016/j.molcel.2018.03.026,
  25. https://doi.org/10.1038/s41467-024-45633-0,
  26. https://doi.org/10.1172/jci175448,
  27. https://doi.org/10.1038/s43018-023-00550-x,
  28. https://doi.org/10.3390/brainsci14010022,
  29. https://doi.org/10.3389/fimmu.2024.1395580,

πŸ“„ View Raw YAML

id: Q96DZ1
gene_symbol: ERLEC1
product_type: PROTEIN
status: IN_PROGRESS
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: >-
  ERLEC1 (also known as XTP3-B or Erlectin) is an ER-resident lectin containing
  two mannose 6-phosphate receptor homology (MRH) domains. It functions as a
  context-dependent triage factor in the endoplasmic reticulum-associated
  degradation (ERAD) pathway, recognizing misfolded glycoproteins via their
  trimmed N-glycan sugar moieties and delivering them to the HRD1-SEL1L ubiquitin
  ligase complex for retrotranslocation and proteasomal degradation. The
  C-terminal MRH domain (MRH2) mediates glycan binding with specificity for
  Man9GlcNAc2 (M9) and Man5-type high-mannose N-glycans exposing a terminal
  alpha-1,6-linked mannose motif (DOI:10.1093/glycob/cwp182,
  DOI:10.1111/febs.12157). ERLEC1 forms a large ER quality control scaffold
  complex together with OS-9, BiP (HSPA5), and the HRD1-SEL1L ubiquitin ligase.
  The long isoform (hXTP3-B-long) associates with this scaffold and can retard
  ERAD of both glycosylated and non-glycosylated substrates, while the short
  isoform is excluded from scaffold formation. SEL1L stabilizes ERLEC1 protein;
  SEL1L depletion causes accelerated ERLEC1 degradation (~40% loss over 10 hours
  in cycloheximide chase) without change in mRNA levels (DOI:10.1111/febs.12157).
  Genetic studies reveal that ERLEC1 and OS9 play redundant and antagonistic roles
  in ERAD: both redundantly promote glycoprotein degradation and stabilize
  SEL1L-HRD1, but ERLEC1 strongly inhibits degradation of non-glycosylated
  substrates, with OS9 antagonizing this inhibition, thereby tuning ERAD substrate
  selectivity (DOI:10.1016/j.molcel.2018.03.026). Mannose trimming by ER
  mannosidase I is required for substrate delivery from EDEM1 to XTP3-B,
  consistent with its role as a lectin-based ERAD cargo receptor rather than a
  chaperone.
alternative_products:
- name: 1 (hXTP3B-long)
  id: Q96DZ1-1
- name: 2 (hXTP3B-short)
  id: Q96DZ1-2
  sequence_note: VSP_015790
- name: '3'
  id: Q96DZ1-3
  sequence_note: VSP_047155
existing_annotations:
- term:
    id: GO:0005788
    label: endoplasmic reticulum lumen
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      IBA annotation placing ERLEC1 in the ER lumen, inferred from phylogenetic
      analysis. This is strongly supported by multiple independent experimental
      studies. Cruciat et al. (PMID:16531414) showed that Erlectin is a luminal
      resident protein of the endoplasmic reticulum. Hosokawa et al.
      (PMID:18502753) confirmed ER lumen localization. Christianson et al.
      (PMID:18264092) also demonstrated ER lumen localization. UniProt annotates
      subcellular location as ER lumen with experimental evidence. ERLEC1 has a
      signal peptide (aa 1-33) and lacks a transmembrane domain, consistent with
      a soluble ER lumen protein retained by the quality control machinery.
    action: ACCEPT
    reason: >-
      ER lumen localization is a core feature of ERLEC1 function as an ERAD
      cargo receptor. The IBA annotation is fully consistent with multiple
      experimental (IDA) demonstrations of ER lumen localization.
    supported_by:
    - reference_id: PMID:16531414
      supporting_text: >-
        Like other members of the MRH family, Erlectin is a luminal resident
        protein of the endoplasmic reticulum
    - reference_id: PMID:18502753
      supporting_text: >-
        hXTP3-B long isoform associates with the HRD1-SEL1L membrane-anchored
        ubiquitin ligase complex and BiP, forming a 27 S ER quality control
        scaffold complex
- term:
    id: GO:0030970
    label: retrograde protein transport, ER to cytosol
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: >-
      IBA annotation for involvement in retrograde protein transport, ER to
      cytosol, inferred from phylogenetic analysis including yeast Yos9p.
      ERLEC1/XTP3-B is a key component of the ERAD pathway that delivers
      misfolded glycoproteins to the HRD1-SEL1L ubiquitin ligase complex for
      retrotranslocation and proteasomal degradation (PMID:18264092,
      PMID:18502753). Hosokawa et al. (PMID:18502753) showed that ERLEC1 forms
      a scaffold complex that provides a platform for recognition and sorting
      of misfolded proteins prior to retrotranslocation into the cytoplasm.
      Groisman et al. (PMID:21062743) demonstrated that mannose trimming is
      required for substrate delivery from EDEM1 to XTP3-B and to late ERAD
      steps. This term is appropriate as ERLEC1 participates in the process
      that moves ER proteins to the cytosol for degradation.
    action: ACCEPT
    reason: >-
      Retrograde protein transport ER to cytosol is a core process that ERLEC1
      participates in as an ERAD cargo receptor. The IBA annotation is well
      supported by experimental evidence from multiple groups showing ERLEC1
      functions in delivering misfolded substrates to the retrotranslocation
      machinery.
    supported_by:
    - reference_id: PMID:18502753
      supporting_text: >-
        this large ER quality control scaffold complex, containing ER lectins,
        a chaperone, and a ubiquitin ligase, provides a platform for the
        recognition and sorting of misfolded glycoproteins as well as
        nonglycosylated proteins prior to retrotranslocation into the cytoplasm
        for degradation
    - reference_id: PMID:18264092
      supporting_text: >-
        OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
        ERAD substrates and, through the SEL1L adaptor, to the
        ER-membrane-embedded ubiquitin ligase Hrd1
    - reference_id: PMID:21062743
      supporting_text: >-
        Our results suggest that mannose trimming enables delivery of a
        substrate glycoprotein from EDEM1 to late ERAD steps through
        association with XTP3-B
- term:
    id: GO:0005783
    label: endoplasmic reticulum
  evidence_type: IEA
  original_reference_id: GO_REF:0000117
  review:
    summary: >-
      IEA annotation from ARBA machine learning placing ERLEC1 in the
      endoplasmic reticulum. This is correct but less specific than
      GO:0005788 (endoplasmic reticulum lumen), which is supported by
      IDA evidence from multiple publications (PMID:16531414, PMID:18264092)
      and IBA evidence. ERLEC1 is a soluble ER lumen protein, not a
      membrane-associated protein, so the more specific ER lumen term is
      more appropriate. However, as an IEA annotation, it is acceptable to
      retain a broader term that is not incorrect.
    action: ACCEPT
    reason: >-
      While GO:0005783 (endoplasmic reticulum) is less specific than the
      experimentally supported GO:0005788 (ER lumen), it is not incorrect.
      The IEA annotation is a broader but valid computational inference.
      The more specific ER lumen localization is already captured by
      separate IDA and IBA annotations.
- term:
    id: GO:0005788
    label: endoplasmic reticulum lumen
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: >-
      IEA annotation mapping ERLEC1 to the ER lumen based on
      UniProtKB/Swiss-Prot subcellular location vocabulary. UniProt annotates
      ERLEC1 subcellular location as "Endoplasmic reticulum lumen" with
      experimental evidence from PMID:16531414 and PMID:18502753. This
      computational mapping is fully consistent with the experimental data.
    action: ACCEPT
    reason: >-
      The IEA mapping from UniProt subcellular location to GO:0005788 is
      correct and consistent with experimental evidence. ERLEC1 ER lumen
      localization is well established.
- term:
    id: GO:0030968
    label: endoplasmic reticulum unfolded protein response
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: >-
      IEA annotation from InterPro (IPR045149, OS-9-like domain) mapping to the
      ER unfolded protein response. ERLEC1 is part of the ER quality control
      machinery but its primary role is in ERAD, not the canonical unfolded
      protein response (UPR) signaling pathway. The UPR is a transcriptional
      signaling response involving IRE1, PERK, and ATF6 pathways that activates
      gene expression to cope with ER stress. ERLEC1 does not participate in
      UPR signaling; rather, it functions downstream as a cargo receptor in
      ERAD, recognizing misfolded glycoproteins and delivering them to the
      HRD1-SEL1L complex for retrotranslocation (PMID:18264092, PMID:18502753).
      The ERAD pathway annotation (GO:0036503) is the more precise term.
    action: MODIFY
    reason: >-
      GO:0030968 (ER unfolded protein response) refers to the UPR signaling
      cascade, not to ERAD per se. ERLEC1 is not a UPR signaling component
      but rather an ERAD cargo receptor. The correct biological process term
      is GO:0036503 (ERAD pathway), which is already annotated separately.
      This IEA annotation likely arises from an overly broad InterPro-to-GO
      mapping for the OS-9-like domain family.
    proposed_replacement_terms:
    - id: GO:0036503
      label: ERAD pathway
- term:
    id: GO:0036503
    label: ERAD pathway
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  review:
    summary: >-
      IEA annotation from InterPro (IPR045149, OS-9-like) mapping to the ERAD
      pathway. This is fully supported by extensive experimental evidence.
      ERLEC1/XTP3-B is a central component of the ERAD pathway, functioning
      as a lectin-based cargo receptor that recognizes misfolded glycoproteins
      and delivers them to the HRD1-SEL1L ubiquitin ligase complex
      (PMID:18264092, PMID:18502753, PMID:21062743). Groisman et al.
      (PMID:21062743) specifically demonstrated that mannose trimming is
      required for substrate delivery from EDEM1 to XTP3-B and to late ERAD
      steps. Christianson et al. (PMID:18264092) showed that XTP3-B binds to
      ERAD substrates and through SEL1L to HRD1, and is required for
      degradation of mutant alpha1-antitrypsin.
    action: ACCEPT
    reason: >-
      The ERAD pathway is the core biological process in which ERLEC1
      participates. The IEA annotation is correct and well supported by
      experimental evidence from multiple independent studies.
- term:
    id: GO:0036503
    label: ERAD pathway
  evidence_type: TAS
  original_reference_id: PMID:21062743
  review:
    summary: >-
      TAS annotation for ERAD pathway involvement based on Groisman et al.
      (PMID:21062743). This paper directly demonstrates that XTP3-B functions
      in the ERAD pathway by showing that mannose trimming by ER mannosidase I
      is required for substrate delivery from EDEM1 to XTP3-B, and that
      inhibition of mannose trimming blocks substrate association with XTP3-B
      and with E3 ubiquitin ligases HRD1 and SCF(Fbs2). This establishes
      ERLEC1 as a lectin acting at a late step in the ERAD pathway, after
      mannose trimming and before ubiquitination and retrotranslocation.
    action: ACCEPT
    reason: >-
      ERAD pathway involvement is the core function of ERLEC1. The TAS
      annotation is well supported by the cited reference, which directly
      demonstrates ERLEC1 function in delivering substrates to late ERAD
      steps in a mannose-trimming-dependent manner.
    supported_by:
    - reference_id: PMID:21062743
      supporting_text: >-
        Our results suggest that mannose trimming enables delivery of a
        substrate glycoprotein from EDEM1 to late ERAD steps through
        association with XTP3-B
    - reference_id: PMID:21062743
      supporting_text: >-
        substrate association with XTP3-B and with the E3 ubiquitin ligases
        HRD1 and SCF(Fbs2) was inhibited
- term:
    id: GO:0051082
    label: unfolded protein binding
  evidence_type: IDA
  original_reference_id: PMID:21062743
  review:
    summary: >-
      GO:0051082 (unfolded protein binding) is being obsoleted (go-ontology#30962).
      The suggested replacements are holdase chaperone activity or protein folding
      chaperone (GO:0044183), neither of which applies to ERLEC1. ERLEC1/XTP3-B is
      an ER lectin that recognizes misfolded glycoproteins via their trimmed N-glycan
      moieties as part of the ERAD pathway (PMID:21062743, PMID:18502753). It is not
      a chaperone. Groisman et al. (PMID:21062743) showed that mannose trimming by
      ER mannosidase I is required for substrate delivery from EDEM1 to XTP3-B,
      establishing ERLEC1 as a lectin-based cargo receptor rather than a protein that
      directly binds unfolded polypeptide chains. Christianson et al. (PMID:18264092)
      demonstrated that the MRH domains of XTP3-B are required for interaction with
      SEL1L but not with substrate, and that XTP3-B and OS-9 are components of
      quality control surveillance pathways that coordinate protein folding with
      membrane dislocation and ubiquitin conjugation. Hosokawa et al. (PMID:18502753)
      showed that hXTP3-B forms a scaffold with HRD1-SEL1L and BiP, and that the
      long isoform retarded ERAD of both glycosylated (NHK) and non-glycosylated
      (NHK-QQQ) substrates. While ERLEC1 does interact with misfolded proteins,
      this interaction is in the context of ERAD substrate recognition and delivery
      to the ubiquitin ligase complex, not chaperone-like unfolded protein binding.
      The ERAD pathway involvement is already captured by GO:0036503.
    action: REMOVE
    reason: >-
      GO:0051082 is being obsoleted. The replacement terms (holdase chaperone,
      foldase chaperone) do not apply to ERLEC1, which is a lectin-based ERAD cargo
      receptor, not a chaperone. ERLEC1 recognizes misfolded glycoproteins through
      their N-glycan sugar moieties (requiring mannose trimming) and delivers them
      to the HRD1-SEL1L ubiquitin ligase complex for degradation. This is substrate
      recognition for ERAD targeting, not chaperone-like binding to unfolded
      polypeptide chains. The relevant biological function is already captured by
      the ERAD pathway annotation (GO:0036503) and retrograde protein transport
      annotation (GO:0030970). Similar to SYVN1, ERLEC1 interacts with misfolded
      proteins as part of the ERAD machinery, which does not constitute unfolded
      protein binding in the chaperone sense.
    additional_reference_ids:
    - PMID:18502753
    - PMID:18264092
    - PMID:16531414
    supported_by:
    - reference_id: PMID:21062743
      supporting_text: >-
        Our results suggest that mannose trimming enables delivery of a
        substrate glycoprotein from EDEM1 to late ERAD steps through
        association with XTP3-B
    - reference_id: PMID:21062743
      supporting_text: >-
        substrate association with XTP3-B and with the E3 ubiquitin ligases
        HRD1 and SCF(Fbs2) was inhibited
    - reference_id: PMID:18264092
      supporting_text: >-
        OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
        ERAD substrates and, through the SEL1L adaptor, to the
        ER-membrane-embedded ubiquitin ligase Hrd1
    - reference_id: PMID:18264092
      supporting_text: >-
        Both proteins contain conserved mannose 6-phosphate receptor homology
        (MRH) domains, which are required for interaction with SEL1L, but not
        with substrate
    - reference_id: PMID:18264092
      supporting_text: >-
        XTP3-B and OS-9 are components of distinct, partially redundant,
        quality control surveillance pathways that coordinate protein folding
        with membrane dislocation and ubiquitin conjugation in mammalian cells
    - reference_id: PMID:18502753
      supporting_text: >-
        hXTP3-B long isoform associates with the HRD1-SEL1L membrane-anchored
        ubiquitin ligase complex and BiP, forming a 27 S ER quality control
        scaffold complex
    - reference_id: PMID:18502753
      supporting_text: >-
        this large ER quality control scaffold complex, containing ER lectins,
        a chaperone, and a ubiquitin ligase, provides a platform for the
        recognition and sorting of misfolded glycoproteins as well as
        nonglycosylated proteins prior to retrotranslocation into the cytoplasm
        for degradation
    - reference_id: PMID:16531414
      supporting_text: >-
        Erlectin functions in N-glycan recognition in the endoplasmic
        reticulum, suggesting that it may regulate glycoprotein traffic
- term:
    id: GO:1904153
    label: negative regulation of retrograde protein transport, ER to cytosol
  evidence_type: IMP
  original_reference_id: PMID:25660456
  review:
    summary: >-
      IMP annotation for negative regulation of retrograde protein transport
      (ER to cytosol) based on Zhong et al. (PMID:25660456). This paper used
      RNAi knockdown and a dislocation-reconstituted GFP (drGFP) assay to
      assess the requirement of ERAD components for dislocation of NHK (null
      Hong Kong variant of alpha1-antitrypsin). The study found that knockdown
      of 7 of 21 ERAD components enhanced NHK dislocation. If ERLEC1 knockdown
      enhanced dislocation, this would be consistent with a negative regulatory
      role. However, this seemingly contradicts the established role of ERLEC1
      as a facilitator of ERAD (delivering substrates to the ubiquitin ligase).
      Hosokawa et al. (PMID:18502753) showed that overexpression of the long
      isoform of hXTP3-B retarded ERAD of both NHK and NHK-QQQ, which is
      consistent with a negative regulatory effect when in excess. This
      paradoxical role may reflect that excess ERLEC1 sequesters substrates or
      blocks the retrotranslocation channel. The annotation captures the
      experimental observation but should be interpreted cautiously as possibly
      reflecting an overexpression/dosage artifact rather than a normal
      physiological function.
    action: KEEP_AS_NON_CORE
    reason: >-
      The annotation captures a real experimental observation (IMP evidence)
      but the negative regulation of retrotranslocation is likely not the
      primary physiological role of ERLEC1. Its core function is as a cargo
      receptor that facilitates ERAD. The negative regulatory effect may
      reflect dosage-dependent or context-dependent modulation. Hosokawa et al.
      (PMID:18502753) also observed that hXTP3-B overexpression retards ERAD,
      consistent with a scaffolding role where excess cargo receptor can
      sequester substrates away from the retrotranslocation machinery.
    additional_reference_ids:
    - PMID:18502753
    supported_by:
    - reference_id: PMID:25660456
      supporting_text: >-
        knockdown of 7 of the 21 components enhanced NHK dislocation
    - reference_id: PMID:18502753
      supporting_text: >-
        both isoforms retard ERAD of the human alpha(1)-antitrypsin variant
        null Hong Kong (NHK), a terminally misfolded glycoprotein
    - reference_id: PMID:18502753
      supporting_text: >-
        The hXTP3-B long isoform strongly inhibited ERAD of NHK-QQQ, which
        lacks all of the N-glycosylation sites of NHK
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-5362412
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-5362412: SYVN1 ubiquitinates Hh
      C-terminal fragments) placing ERLEC1 in the ER quality control
      compartment (ERQC). The ERQC is a pericentriolar ER-derived compartment
      where ERAD machinery concentrates along with misfolded substrates.
      Groisman et al. (PMID:21062743) showed that XTP3-B associates with ERAD
      substrates and E3 ligases in a mannose-trimming-dependent manner,
      consistent with localization to the ERQC. The Reactome entry describes
      ERLEC1 as a lectin in the ERAD machinery that helps target Hedgehog
      C-terminal fragments for degradation. This is a reasonable localization
      annotation for ERLEC1 given its role in ERAD substrate recognition.
    action: ACCEPT
    reason: >-
      ERQC localization is consistent with ERLEC1 function in ERAD. As a
      cargo receptor that concentrates with ERAD machinery and substrates,
      ERLEC1 localizes to this quality control compartment. Multiple
      Reactome entries reference the same biological role; this is one of
      many duplicate TAS annotations from different Reactome reactions.
    supported_by:
    - reference_id: PMID:21062743
      supporting_text: >-
        substrate association with XTP3-B and with the E3 ubiquitin ligases
        HRD1 and SCF(Fbs2) was inhibited
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-5362437
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-5362437: C-terminal Hh fragments
      are bound by lectins). This Reactome entry explicitly states that
      depletion of OS9 and ERLEC1 abrogates degradation of Hh-C fragments,
      and that they may target Hh-C to the retrotranslocation channel via
      interaction with SEL1. ERQC localization is appropriate for ERLEC1
      given its established role as an ERAD lectin cargo receptor.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a different Reactome
      reaction. Same rationale as for R-HSA-5362412: ERLEC1 localizes to
      the ERQC as part of its ERAD cargo receptor function.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-5362441
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-5362441: C-terminal Hh fragments
      are recruited to SEL1:SYVN1 at the ER membrane). ERLEC1 participates
      in recruiting substrates to the SEL1L-SYVN1 complex at the ER membrane,
      consistent with ERQC localization.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a different Reactome
      reaction describing the same ERAD process for Hh fragments.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-5362450
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-5362450: Hh processing variants
      bind lectins). This entry describes how OS9 and ERLEC1 lectins are
      required for degradation of Hh processing-defective variants via the
      ERAD pathway, consistent with ERQC localization.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a different Reactome
      reaction describing ERAD of Hedgehog processing variants.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-5362459
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-5362459: VCP-catalyzed ATP
      hydrolysis promotes the translocation of Hh-C into the cytosol).
      ERLEC1 is part of the ERAD machinery that operates within the ERQC.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      describing the VCP-dependent retrotranslocation step for Hh-C
      fragments in which ERLEC1 participates upstream.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-5387386
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-5387386: Hh processing variants
      are recruited to SEL1:SYVN at the ER membrane). ERLEC1 participates
      in recruiting Hh processing variants to the ubiquitin ligase complex.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction.
      Same biological context as other Hh ERAD entries.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-5387389
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-5387389: Hh processing variants
      are translocated to the cytosol in a VCP-dependent manner). Part of
      the Hh ERAD pathway in which ERLEC1 acts as cargo receptor.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      in the Hh ERAD pathway.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-5483238
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-5483238: Hh processing variants
      are ubiquitinated). ERLEC1 functions upstream of the ubiquitination
      step in ERAD, within the ERQC.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      describing Hh variant ubiquitination in which ERLEC1 participates.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-8866542
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-8866542: VCP-catalyzed ATP
      hydrolysis promotes the translocation of misfolded CFTR into the
      cytosol). ERLEC1 is part of the ERAD machinery for misfolded CFTR,
      consistent with ERQC localization.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      describing CFTR ERAD in which ERLEC1 participates as cargo receptor.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-8866546
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-8866546: RNF5 and RNF185
      ubiquitinate misfolded CFTR). ERLEC1 operates within the ERQC
      as part of the CFTR ERAD pathway.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      in the CFTR ERAD pathway.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-8866551
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-8866551: CFTR binds components
      of the ERAD machinery for ubiquitination and degradation). ERLEC1
      is one of the ERAD components that binds misfolded CFTR in the ERQC.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      describing CFTR binding to ERAD components including ERLEC1.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-8866854
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-8866854: VCP-catalyzed ATP
      hydrolysis promotes the translocation of CFTR F508del into the
      cytosol). ERLEC1 participates in ERAD of the common CF-causing
      CFTR F508del mutation, within the ERQC.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      in the CFTR F508del ERAD pathway.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-8866856
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-8866856: RNF5 and RNF185
      ubiquitinate CFTR F508del). ERLEC1 is part of the ERAD machinery
      for CFTR F508del within the ERQC.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      in the CFTR F508del ERAD pathway.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-8866857
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-8866857: CFTR F508del binds
      components of the ERAD machinery for ubiquitination and degradation).
      ERLEC1 is an ERAD component that binds misfolded CFTR F508del.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      describing CFTR F508del ERAD.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9931264
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-9931264: Active transport of
      ubiquitinated CD274 from ER to cytosol). ERLEC1 participates in
      ERAD of CD274 (PD-L1) within the ERQC.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      describing CD274 ERAD.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9931298
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-9931298: Ubiquitination of CD274
      by ERAD complex). ERLEC1 is part of the ERAD complex that
      ubiquitinates CD274.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      describing CD274 ubiquitination by ERAD.
- term:
    id: GO:0044322
    label: endoplasmic reticulum quality control compartment
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9931313
  review:
    summary: >-
      TAS annotation from Reactome (R-HSA-9931313: p-S195-CD274 binds
      ERAD complex). ERLEC1 is part of the ERAD complex that binds
      phosphorylated CD274 for degradation.
    action: ACCEPT
    reason: >-
      Duplicate ERQC localization annotation from a Reactome reaction
      describing CD274 ERAD. Last of the 16 duplicate Reactome TAS
      annotations for ERQC localization, all consistent with ERLEC1
      role in ERAD.
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:18502753
  review:
    summary: >-
      IPI annotation for protein binding based on Hosokawa et al.
      (PMID:18502753), with UniProtKB:Q13438 (OS-9/OS9) as the interacting
      partner. This paper showed that hXTP3-B forms an ER quality control
      scaffold complex with OS-9, HRD1-SEL1L, and BiP. The interaction
      between ERLEC1 and OS-9 is in the context of the ERAD scaffold complex.
      While the interaction is real, GO:0005515 (protein binding) is
      uninformative. A more specific term such as GO:0051787 (misfolded
      protein binding) would capture the functional context, though the
      direct interaction with OS-9 is more of a scaffold co-complex
      interaction. The term could be modified to misfolded protein binding
      to reflect ERLEC1 function, but since the with/from is OS-9 (a
      co-complex partner, not a misfolded substrate), the annotation as
      stated is simply documenting a physical interaction.
    action: MODIFY
    reason: >-
      GO:0005515 (protein binding) is uninformative per curation guidelines.
      ERLEC1 binds misfolded glycoproteins as a cargo receptor. The more
      informative term is GO:0051787 (misfolded protein binding), which
      captures ERLEC1 core molecular function of recognizing misfolded
      glycoprotein substrates for ERAD.
    proposed_replacement_terms:
    - id: GO:0051787
      label: misfolded protein binding
    supported_by:
    - reference_id: PMID:18502753
      supporting_text: >-
        this large ER quality control scaffold complex, containing ER lectins,
        a chaperone, and a ubiquitin ligase, provides a platform for the
        recognition and sorting of misfolded glycoproteins as well as
        nonglycosylated proteins prior to retrotranslocation into the cytoplasm
        for degradation
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IDA
  original_reference_id: PMID:16531414
  review:
    summary: >-
      IDA annotation for protein binding based on Cruciat et al.
      (PMID:16531414). This paper identified Erlectin as a protein that
      interacts with Kremen2 (KREMEN2), a coreceptor for Dickkopf1 in Wnt
      signaling. The interaction with Kremen2 is glycosylation-dependent
      (abolished by Kremen2 deglycosylation) and requires the second MRH
      domain of Erlectin (G379S mutation abolishes binding). Overexpression
      of Erlectin inhibited transport of Krm2 to the cell surface. This
      interaction reflects ERLEC1 lectin activity in glycoprotein quality
      control. GO:0005515 is uninformative; the functional activity is
      better captured by misfolded protein binding or N-glycan recognition.
    action: MODIFY
    reason: >-
      GO:0005515 (protein binding) is uninformative per curation guidelines.
      The interaction with Kremen2 via N-glycan recognition represents
      ERLEC1 lectin function in the ER. The more informative term is
      GO:0051787 (misfolded protein binding), reflecting ERLEC1 role in
      recognizing glycoproteins for ER quality control.
    proposed_replacement_terms:
    - id: GO:0051787
      label: misfolded protein binding
    supported_by:
    - reference_id: PMID:16531414
      supporting_text: >-
        Erlectin functions in N-glycan recognition in the endoplasmic
        reticulum, suggesting that it may regulate glycoprotein traffic
    - reference_id: PMID:16531414
      supporting_text: >-
        It contains two MRH domains, of which one is essential for Krm2
        binding, and this interaction is abolished by Krm2 deglycosylation
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:18264092
  review:
    summary: >-
      IPI annotation for protein binding based on Christianson et al.
      (PMID:18264092), with multiple interacting partners (UniProtKB:P11021
      HSPA5/BiP, UniProtKB:Q86TM6 SYVN1/HRD1, UniProtKB:Q9UBV2 SEL1L).
      This paper showed that XTP3-B binds to ERAD substrates and through
      SEL1L to HRD1. The MRH domains are required for interaction with
      SEL1L but not with substrate. XTP3-B and OS-9 are components of
      distinct, partially redundant quality control surveillance pathways.
      GO:0005515 is uninformative; ERLEC1 interactions with SEL1L and
      HRD1 reflect its role as a substrate adaptor for the ERAD ubiquitin
      ligase complex.
    action: MODIFY
    reason: >-
      GO:0005515 (protein binding) is uninformative per curation guidelines.
      The interactions documented here are functionally significant: ERLEC1
      binding to SEL1L and HRD1 via its MRH domains reflects its role as
      a substrate adaptor that bridges misfolded glycoproteins to the E3
      ubiquitin ligase complex. The most informative molecular function
      term would be GO:0051787 (misfolded protein binding), capturing
      ERLEC1 core activity of recognizing misfolded substrates.
    proposed_replacement_terms:
    - id: GO:0051787
      label: misfolded protein binding
    supported_by:
    - reference_id: PMID:18264092
      supporting_text: >-
        OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
        ERAD substrates and, through the SEL1L adaptor, to the
        ER-membrane-embedded ubiquitin ligase Hrd1
    - reference_id: PMID:18264092
      supporting_text: >-
        Both proteins contain conserved mannose 6-phosphate receptor homology
        (MRH) domains, which are required for interaction with SEL1L, but not
        with substrate
- term:
    id: GO:0005788
    label: endoplasmic reticulum lumen
  evidence_type: IDA
  original_reference_id: PMID:16531414
  review:
    summary: >-
      IDA annotation for ER lumen localization based on Cruciat et al.
      (PMID:16531414). This paper demonstrated by immunofluorescence and
      mass spectrometry that Erlectin is a luminal resident protein of the
      endoplasmic reticulum. ERLEC1 has a signal peptide (aa 1-33) and
      lacks a transmembrane domain, consistent with a soluble ER lumen
      protein.
    action: ACCEPT
    reason: >-
      ER lumen localization is a well-established core feature of ERLEC1,
      directly demonstrated by Cruciat et al. The IDA evidence is strong
      and consistent with the protein sequence (signal peptide, no TM
      domain) and with other experimental studies.
    supported_by:
    - reference_id: PMID:16531414
      supporting_text: >-
        Like other members of the MRH family, Erlectin is a luminal resident
        protein of the endoplasmic reticulum
- term:
    id: GO:0005788
    label: endoplasmic reticulum lumen
  evidence_type: IDA
  original_reference_id: PMID:18264092
  review:
    summary: >-
      IDA annotation for ER lumen localization based on Christianson et al.
      (PMID:18264092). This paper confirmed that XTP3-B/Erlectin is an
      ER-resident glycoprotein, consistent with ER lumen localization
      established by Cruciat et al. (PMID:16531414) and Hosokawa et al.
      (PMID:18502753).
    action: ACCEPT
    reason: >-
      Independent experimental confirmation of ER lumen localization by
      a second research group. Consistent with all other evidence.
    supported_by:
    - reference_id: PMID:18264092
      supporting_text: >-
        OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
        ERAD substrates and, through the SEL1L adaptor, to the
        ER-membrane-embedded ubiquitin ligase Hrd1
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:16531414
  review:
    summary: >-
      IPI annotation for protein binding based on Cruciat et al.
      (PMID:16531414), with UniProtKB:Q8K1S7 (mouse Kremen2) as the
      interacting partner. This paper identified Erlectin in a proteomic
      approach as a protein that interacts with Kremen2. The interaction
      is glycosylation-dependent and requires the MRH domain of Erlectin.
      GO:0005515 is uninformative; this interaction reflects ERLEC1 lectin
      activity in N-glycan recognition and glycoprotein quality control.
    action: MODIFY
    reason: >-
      GO:0005515 (protein binding) is uninformative per curation guidelines.
      The interaction with glycosylated Kremen2 via the MRH domain reflects
      ERLEC1 lectin function. The more informative term is GO:0051787
      (misfolded protein binding), as ERLEC1 recognizes glycoproteins in
      the context of ER quality control.
    proposed_replacement_terms:
    - id: GO:0051787
      label: misfolded protein binding
    supported_by:
    - reference_id: PMID:16531414
      supporting_text: >-
        It contains two MRH domains, of which one is essential for Krm2
        binding, and this interaction is abolished by Krm2 deglycosylation
    - reference_id: PMID:16531414
      supporting_text: >-
        The overexpression of Erlectin inhibits transport of Krm2 to the
        cell surface
- term:
    id: GO:0051787
    label: misfolded protein binding
  evidence_type: IDA
  original_reference_id: PMID:18264092
  review:
    summary: >-
      NEW annotation proposed for GO:0051787 (misfolded protein binding).
      Multiple studies demonstrate that ERLEC1/XTP3-B binds to misfolded
      glycoproteins in the ER. Christianson et al. (PMID:18264092) showed
      that XTP3-B binds to ERAD substrates (mutant alpha1-antitrypsin NHK).
      Hosokawa et al. (PMID:18502753) showed that hXTP3-B forms a scaffold
      complex for recognition and sorting of misfolded glycoproteins and
      nonglycosylated proteins. Groisman et al. (PMID:21062743) demonstrated
      that substrate association with XTP3-B depends on mannose trimming.
      This term is more informative than the generic GO:0005515 (protein
      binding) annotations currently present and accurately captures
      ERLEC1 core molecular function as a lectin that recognizes misfolded
      glycoprotein substrates for ERAD.
    action: NEW
    reason: >-
      GO:0051787 (misfolded protein binding) is the most informative
      molecular function term for ERLEC1. It replaces the uninformative
      GO:0005515 (protein binding) annotations and provides the correct
      replacement for the obsolescent GO:0051082 (unfolded protein binding).
      ERLEC1 specifically binds misfolded glycoproteins (not simply unfolded
      polypeptides) as a cargo receptor for ERAD.
    additional_reference_ids:
    - PMID:18502753
    - PMID:21062743
    supported_by:
    - reference_id: PMID:18264092
      supporting_text: >-
        OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
        ERAD substrates and, through the SEL1L adaptor, to the
        ER-membrane-embedded ubiquitin ligase Hrd1
    - reference_id: PMID:18502753
      supporting_text: >-
        this large ER quality control scaffold complex, containing ER lectins,
        a chaperone, and a ubiquitin ligase, provides a platform for the
        recognition and sorting of misfolded glycoproteins as well as
        nonglycosylated proteins prior to retrotranslocation into the cytoplasm
        for degradation
    - reference_id: PMID:21062743
      supporting_text: >-
        substrate association with XTP3-B and with the E3 ubiquitin ligases
        HRD1 and SCF(Fbs2) was inhibited
- term:
    id: GO:0097466
    label: ubiquitin-dependent glycoprotein ERAD pathway
  evidence_type: TAS
  original_reference_id: PMID:21062743
  review:
    summary: >-
      NEW annotation proposed for GO:0097466 (ubiquitin-dependent glycoprotein
      ERAD pathway). This term is more specific than GO:0036503 (ERAD pathway)
      and captures the fact that ERLEC1 specifically functions in the
      glycoprotein-specific branch of ERAD. Groisman et al. (PMID:21062743)
      showed that mannose trimming of N-glycans is required for substrate
      delivery from EDEM1 to XTP3-B, establishing ERLEC1 as a lectin that
      acts specifically in glycoprotein ERAD. The broader GO:0036503 (ERAD
      pathway) annotation should be retained as well, since Hosokawa et al.
      (PMID:18502753) showed that the long isoform also affects ERAD of the
      non-glycosylated NHK-QQQ substrate.
    action: NEW
    reason: >-
      GO:0097466 is a more specific child term of GO:0036503 that precisely
      captures ERLEC1 role in the glycoprotein-specific branch of ERAD,
      where it recognizes trimmed N-glycans on misfolded substrates. This
      provides higher annotation specificity while the broader ERAD pathway
      term is retained for the non-glycoprotein ERAD role.
    additional_reference_ids:
    - PMID:18264092
    - PMID:18502753
    supported_by:
    - reference_id: PMID:21062743
      supporting_text: >-
        Our results suggest that mannose trimming enables delivery of a
        substrate glycoprotein from EDEM1 to late ERAD steps through
        association with XTP3-B
    - reference_id: PMID:21062743
      supporting_text: >-
        the mannosidase inhibitor kifunensine or ERManI knockdown do not
        affect binding of an ERAD substrate glycoprotein to EDEM1. In
        contrast, substrate association with XTP3-B and with the E3
        ubiquitin ligases HRD1 and SCF(Fbs2) was inhibited
core_functions:
- description: >-
    ERLEC1 functions as a lectin-based cargo receptor and context-dependent triage
    factor in the ERAD pathway. Its C-terminal MRH domain (MRH2) binds
    Man9GlcNAc2 (M9) and Man5-type high-mannose N-glycans, specifically
    recognizing a terminal alpha-1,6-linked mannose motif that is exposed during
    progressive demannosylation of misfolded glycoproteins (DOI:10.1093/glycob/cwp182,
    DOI:10.1111/febs.12157). ERLEC1 delivers recognized substrates to the
    HRD1-SEL1L ubiquitin ligase complex for retrotranslocation and proteasomal
    degradation. Mannose trimming by ER mannosidase I is required for substrate
    delivery from EDEM1 to ERLEC1. SEL1L stabilizes ERLEC1 protein within the
    ERAD complex (DOI:10.1111/febs.12157). Genetic studies reveal that ERLEC1 and
    OS9 have redundant roles in promoting glycoprotein ERAD but antagonistic roles
    regarding non-glycosylated substrates: ERLEC1 inhibits degradation of
    non-glycosylated proteins, with OS9 counteracting this inhibition, thereby
    tuning ERAD substrate selectivity and fidelity (DOI:10.1016/j.molcel.2018.03.026).
  molecular_function:
    id: GO:0051787
    label: misfolded protein binding
  directly_involved_in:
    - id: GO:0036503
      label: ERAD pathway
    - id: GO:0097466
      label: ubiquitin-dependent glycoprotein ERAD pathway
    - id: GO:0030970
      label: retrograde protein transport, ER to cytosol
  locations:
    - id: GO:0005788
      label: endoplasmic reticulum lumen
    - id: GO:0044322
      label: endoplasmic reticulum quality control compartment
  supported_by:
    - reference_id: PMID:18264092
      supporting_text: >-
        OS-9 and XTP3-B/Erlectin are ER-resident glycoproteins that bind to
        ERAD substrates and, through the SEL1L adaptor, to the
        ER-membrane-embedded ubiquitin ligase Hrd1
    - reference_id: PMID:21062743
      supporting_text: >-
        Our results suggest that mannose trimming enables delivery of a
        substrate glycoprotein from EDEM1 to late ERAD steps through
        association with XTP3-B
    - reference_id: PMID:18502753
      supporting_text: >-
        this large ER quality control scaffold complex, containing ER lectins,
        a chaperone, and a ubiquitin ligase, provides a platform for the
        recognition and sorting of misfolded glycoproteins as well as
        nonglycosylated proteins prior to retrotranslocation into the cytoplasm
        for degradation
references:
- id: GO_REF:0000002
  title: Gene Ontology annotation through association of InterPro records with GO
    terms
  findings: []
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location
    vocabulary mapping, accompanied by conservative changes to GO terms applied by
    UniProt
  findings: []
- id: GO_REF:0000117
  title: Electronic Gene Ontology annotations created by ARBA machine learning models
  findings: []
- id: PMID:16531414
  title: The MRH protein Erlectin is a member of the endoplasmic reticulum synexpression
    group and functions in N-glycan recognition.
  findings: []
- id: PMID:18264092
  title: OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin
    ligase complex for ERAD.
  findings: []
- id: PMID:18502753
  title: Human XTP3-B forms an endoplasmic reticulum quality control scaffold with
    the HRD1-SEL1L ubiquitin ligase complex and BiP.
  findings: []
- id: PMID:21062743
  title: Mannose trimming is required for delivery of a glycoprotein from EDEM1 to
    XTP3-B and to late endoplasmic reticulum-associated degradation steps.
  findings: []
- id: PMID:25660456
  title: Identification of ERAD components essential for dislocation of the null Hong
    Kong variant of Ξ±-1-antitrypsin (NHK).
  findings: []
- id: DOI:10.1093/glycob/cwp182
  title: Human XTP3-B binds to alpha1-antitrypsin variant nullHong Kong via the C-terminal
    MRH domain in a glycan-dependent manner.
  findings:
  - statement: >-
      ERLEC1/XTP3-B C-terminal MRH domain mediates binding to Man9GlcNAc2 and
      Man5-type high-mannose N-glycans with specificity for a terminal
      ManΞ±1,6Man motif
  - statement: >-
      Glycan-dependent binding to misfolded alpha1-antitrypsin NHK was abolished
      by Endo H treatment (p < 0.001)
- id: DOI:10.1111/febs.12157
  title: Endoplasmic reticulum lectin XTP3-B inhibits endoplasmic reticulum-associated
    degradation of a misfolded alpha1-antitrypsin variant.
  findings:
  - statement: >-
      ERLEC1/XTP3-B inhibits ERAD of misfolded alpha1-antitrypsin NHK carrying
      M9 glycans, acting as a negative regulator that may protect newly
      synthesized glycoproteins from premature degradation
  - statement: >-
      Lectin activity is required for substrate engagement but not for SEL1L
      association
  - statement: >-
      SEL1L depletion causes accelerated ERLEC1 degradation (~40% protein loss
      over 10 hours in cycloheximide chase, mRNA unchanged), indicating SEL1L
      stabilizes ERLEC1 protein
- id: DOI:10.1016/j.molcel.2018.03.026
  title: Redundant and antagonistic roles of XTP3B and OS9 in decoding glycan and non-glycan
    degrons in ER-associated degradation.
  findings:
  - statement: >-
      OS9 and XTP3B redundantly promote glycoprotein ERAD and stabilize the
      SEL1L-HRD1 complex
  - statement: >-
      XTP3B strongly inhibits degradation of non-glycosylated substrates, with
      OS9 antagonizing this inhibition
  - statement: >-
      Relative abundance of OS9 vs XTP3B and distribution of glycan vs
      non-glycan degrons within substrates shapes ERAD fidelity and
      processivity
- id: DOI:10.1093/glycob/cwq013
  title: The role of MRH domain-containing lectins in ERAD.
  findings:
  - statement: >-
      Review placing ERLEC1/XTP3-B and OS-9 as MRH-domain lectins that decode
      glycan-based degradation signals and associate with the SEL1L-HRD1 ERAD
      complex
- id: DOI:10.1038/s41467-024-45633-0
  title: SEL1L-HRD1 interaction is required to form a functional HRD1 ERAD complex.
  findings:
  - statement: >-
      SEL1L hypomorphic variant SEL1L-S658P attenuates SEL1L-HRD1 interaction
      (~5-fold reduction) while preserving SEL1L-lectin interactions with
      OS9/ERLEC1
  - statement: >-
      ERLEC1 interaction with SEL1L is maintained even when the overall ERAD
      complex is compromised
- id: Reactome:R-HSA-5362412
  title: SYVN1 ubiquitinates Hh C-terminal fragments
  findings: []
- id: Reactome:R-HSA-5362437
  title: C-terminal Hh fragments are bound by lectins
  findings: []
- id: Reactome:R-HSA-5362441
  title: C-terminal Hh fragments are recruited to SEL1:SYVN1 at the ER membrane
  findings: []
- id: Reactome:R-HSA-5362450
  title: Hh processing variants bind lectins
  findings: []
- id: Reactome:R-HSA-5362459
  title: VCP-catalyzed ATP hydrolysis promotes the translocation of Hh-C into the
    cytosol
  findings: []
- id: Reactome:R-HSA-5387386
  title: Hh processing variants are recruited to SEL1:SYVN at the ER membrane
  findings: []
- id: Reactome:R-HSA-5387389
  title: Hh processing variants are translocated to the cytosol in a VCP-dependent
    manner
  findings: []
- id: Reactome:R-HSA-5483238
  title: Hh processing variants are ubiquitinated
  findings: []
- id: Reactome:R-HSA-8866542
  title: VCP-catalyzed ATP hydrolysis promotes the translocation of misfolded CFTR
    into the cytosol
  findings: []
- id: Reactome:R-HSA-8866546
  title: RNF5 and RNF185 ubiquitinate misfolded CFTR
  findings: []
- id: Reactome:R-HSA-8866551
  title: CFTR binds components of the ERAD machinery for ubiquitination and degradation
  findings: []
- id: Reactome:R-HSA-8866854
  title: VCP-catalyzed ATP hydrolysis promotes the translocation of CFTR F508del into
    the cytosol
  findings: []
- id: Reactome:R-HSA-8866856
  title: RNF5 and RNF185 ubiquitinate CFTR F508del
  findings: []
- id: Reactome:R-HSA-8866857
  title: CFTR F508del binds components of the ERAD machinery for ubiquitination and
    degradation
  findings: []
- id: Reactome:R-HSA-9931264
  title: Active transport of ubiquitinated CD274 from ER to cytosol
  findings: []
- id: Reactome:R-HSA-9931298
  title: Ubiquitination of CD274 by ERAD complex
  findings: []
- id: Reactome:R-HSA-9931313
  title: p-S195-CD274 binds ERAD complex
  findings: []